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PHYSICOCHEMICAL AND STRUCTURAL ANALYSIS OF POLYMERS AS 
PUTATIVE DRUGS 
 
By Meghan Lee Thompson, PhD 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2015 
 
Director: Dr. Umesh Desai 
Professor, Department of Medicinal Chemistry 
 
 
 
Developing polymers as drugs is challenging work, but the therapeutic utility of 
polymers is promising for the treatment of many disease states. Heparin, low molecular 
weight heparins (LMWHs), and other glycosaminoglycans (GAGs) or GAG-like molecules 
have therapeutic potential in clotting disorders, bladder pain, osteoarthritis, and tumor 
metastasis.1,2,3 For LMWHs, the FDA uses five criteria to describe their similarities and 
differences: source of UFH it is synthesized from, physicochemical characteristics, 
xv 
 
structural composition, in vitro biological activity, and in vivo pharmacodynamics profile.4 
Two of those criteria, the biological activity and pharmacodynamics, have been reported 
for the promising polymers known as sulfated low molecular weight lignin (LMWLs), 
originally developed as heparin mimetics.  
Sulfated LMWLs have shown good activity as anticoagulants by allosterically 
inhibiting thrombin, as well as promising agents for treating emphysema through inhibition 
of elastolysis, oxidation, and inflammation5-9 Sulfated LMWLs are chemo-enzymatically 
synthesized from starting monomers caffeic, ferulic, and sinapic acid into sulfated 
dehydropolymers known as CDS, FDS, and SDS. In effort to fill in the gap of information 
about the LMWLs and further their development as drugs, their structural composition 
and physicochemical characteristics were defined in this work.   
The molecular weight distribution profile of the sulfated LMWLs from size exclusion 
chromatography performed on a high pressure liquid chromatography system (SEC-
HPLC) changed from bimodal when no surfactant is used in the mobile phase of the HPLC 
to unimodal when Tween 80 is used in the mobile phase. This indicates that some large 
molecular weight species, likely an aggregate of smaller molecular weight chains, are 
disrupted when surfactant is present. The resulting estimates of molecular weight 
calculated when surfactant is used in the mobile phase resulted in peak average 
molecular weights of 5700 Da for CDS, 7400 Da for FDS, and 4300 Da for SDS. These 
molecular weights are 17-45% higher and can be considered more accurate than the 
previously reported molecular weights (CDS: 3320 Da, FDS: 4120 Da, SDS: 3550 Da) 
because they were measured directly whereas previous estimates were calculated from 
SEC-HPLC data of the unsulfated LMWL precursors. Elemental analysis and 
xvi 
 
octanol:water distribution coefficient measurements were also performed on the LMWL 
library, revealing information about the level of sulfation and hydrophobic character of the 
sulfated LMWLs.  
 
 
1 
 
1. Drug Development of Polymers 
1.1 Polymers as drugs 
The use of polymers in biomedicine has grown significantly in the last four decades 
and the unique physiochemical properties of polymers have been exploited for a variety 
of applications.10 Originally, polymers were recognized to be useful as carriers for site 
specific and sustained delivery of therapeutic agents as polymer-drug conjugate 
systems.10 However, polymers themselves can be intrinsically bioactive and researchers’ 
interest in developing polymers acting as active pharmaceutical ingredients is relatively a 
more recent phenomenon.10 Polymers offer advantages over classic small molecule drug 
candidates due to high molecular weight characteristics, even though these features do 
not fit most “drug-likeness” definitions and violate “Lipinski’s Rules.”10 Benefits of 
polymers as drugs include: lower toxicity, greater specificity, and polyvalency (enhanced 
activity from multiple interactions with disease targets).10 Polymers may have lower 
toxicity due to their high molecular weight characteristics that minimize absorption from 
the site of action (such as the lung or the gut) and reduce off-target side effects. However, 
some drug discovery and development scientists still consider polymeric drugs with 
significant skepticism due to concerns with their broad molecular weight distribution 
(polydispersity), poor oral bioavailability due to high molecular weight, stability in solution, 
and compositional/  structural heterogeneity as shortcomings that impede development 
and approval.10 
Although developed polymeric drugs have only recently entered routine clinical 
practice, natural polymers have been used in medicine for several millennia.11 In modern 
times, the need for more careful identification of specific natural product macromolecular 
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drugs and more rigorous definition of the molecular basis of their mechanism of action is 
paramount to developing approvable polymeric drugs. Divinylether-maleic anhydride 
copolymer was one of the first biologically active polymeric drugs and was clinically tested 
in the 1960s as an anticancer agent.10,11 Unfortunately, it failed clinical testing due to 
severe toxicity related to subtle changes in polymer molecular weight and intravenous 
route of administration.11 Development of therapeutic polymers and translation to the 
clinic is therefore subject to many challenges, such as: industrial scale manufacture, 
validated analytical techniques required to confirm identity and batch to batch 
reproducibility of the often heterogeneous, hybrid macromolecular constructs, and 
pharmaceutical formulations that ensure shelf-life stability and rapid solubilization of 
particle-free solutions for safe injection.11 Drug development of heterogeneous, 
polydisperse polymers requires complex structural and physicochemical characterization, 
such as determination of molecular weight distributions (such as those described in this 
work), to ensure equivalency of preparations.  
1.2 Glycans 
Glycans are saccharides and represent a wide array of structurally diverse 
compounds that contain carbohydrate constituents and may be simple sugars 
(monosaccharides) or polymeric oligosaccharides linked through inter-glycoside bonds. 
Glycoscience, the study of these glycans and their interactions with biomacromolecules, 
has historically received less focus and funding in comparison to protein or nucleic acid 
science, leaving lots of room for growth and discovery. The National Research Council 
Committee on Assessing the Importance and Impact of Glycomics and Glycosciences 
has called for an increased focus on glycoscience in a 2012 report promising great 
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advances in the field.12  Rapid enhancements in our ability to understand and take 
advantage of carbohydrate-protein interactions and new developments in glycoscience 
techniques facilitate the success of research in this field.12,13  
Glycans and proteins make up the matrix on the surface of all mammalian cells 
known as the glycocalyx (Figure 1).14,15 The glycocalyx serves as the first site of contact 
between cells as well as between cells and pathogens. Biological information encoded in 
the glycans expressed in the glycocalyx is designated the glycocode, which can be 
recognized specifically by lectins (carbohydrate binding proteins) to exert concrete 
biological functions (e.g., cell signaling, molecular recognition, inflammation, and 
immunity).15,16 Taking advantage of the functionality of protein-carbohydrate interactions 
is therefore a promising area for drug development to target a myriad of disease states.  
 
Figure 1. The glycocalyx that makes up the surface of all mammalian cells and contains 
O-glycans, N-glycans, glycan binding proteins, and other glycans5  
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Glycans come in many forms linked to other biomolecules: glycolipids, 
peptidoglycans, and glycoproteins. These glycoconjugates have a “glycone” portion 
consisting of the glycan and an “aglycone” portion composed of the non-carbohydrate 
part of the molecule. Glycolipids are lipids that have glycan chains attached such as 
glycerolipids, sphingolipids, and gangliosides. Peptidoglycans form the bacterial cell wall 
and consist of alternating polymer units of a N-acetylglucosamine and a N-acetylmuramic 
acid that contains peptide chains. The majority of proteins are glycosylated, termed 
glycoproteins, which are proteins that have been modified with glycan chains on 
asparagine, serine, or threonine residues. Proteoglycans are a subclass of glycoproteins 
that represent proteins which have been heavily glycosylated with glycosaminoglycan 
(GAG) chains, such as decorin, sergylycin, perlecan, and aggrecan. Glycoproteins can 
be divided into two general classes: N-linked (to asparagine) or O-linked (to seronine or 
threonine).4N-glycans most commonly consist of N-acetylglucosamine residue covalently 
bonded to asparagine. N-glycans are important physiologically for protein quality control 
and aid in optimal folding of glycoproteins as chaperones. Pathologies involving N-glycans 
include cystic fibrosis, liver cirrhosis, and cancer. Example structures of N- and O-linked 
glycans are below (Figure 2).4,17 
O-glycans consist of two major types: mucins and nonmucins. Mucins are typically 
found in mucous secretions and as transmembrane glycoproteins with glycans exposed 
to the external environment. Mucins are hydrophilic, negatively charged, contribute to 
adhesion, and retain water and salt. There are many types of nonmucins that are 
abundant in the cytoplasm and nucleus, though they were believed to be nonexistent just 
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a decade ago. O-glycans serve to regulate the activity of various transcription factors and 
control the specificity and activity of transcription machinery.4 
 
 
Figure 2. Example structures of typical N- and O-linked glycans9  
 
1.3 Glycosaminoglycans  
As mentioned above glycosaminoglycans (GAGs) are an important part of 
proteoglycans and have considerable potential for therapeutic use due to their diverse 
array of biological activities and potential disease targets. GAGs and GAG-like molecules 
used as drugs may have lower toxicity due to their similarity in structure to endogenous 
species in the body because all human cells are coated with glycans, making drugs that 
are GAGs or conjugated with GAG-like polymers more biocompatible.  Despite 
challenges discussed above that may potentially limit polymeric drug development, 
several GAGs have achieved clinical approval and are in use as medicines today, 
including anticoagulants: heparin, low molecular weight heparins, and fondaparinux, as 
well as: hyaluronic acid (for osteoarthritis and wound healing) and chondroitin 
sulfate/glucosamine (for osteoarthritis).4  
6 
 
Heparan sulfate is a GAG similar to heparin (both are biosynthesized as 
copolymers of N-acetylglucosamine linked to either uronic acid or glatactose), but heparan 
sulfate is made by virtually all cells in contrast to heparin which is made solely by 
connective tissue-type mast cells (Figure 3). Heparan sulfate may contain anticoagulant 
activity, but is typically much less active than heparin.17  During biosynthesis, heparin 
undergoes more extensive sulfation resulting in a sulfate to hexosamine ratio of 1.8-2.6 
in comparison with 0.8-1.8 for heparan sulfate.17  Heparin also undergoes a greater 
degree of uronic acid epimerization, with 80% or more of the N-acetylglucosamine 
residues N-acetylated and N-sulfated, whereas only 40-60% epimerize in heparan sulfate. 
Iduronic acid residues make up 30-50% of heparan sulfate, but more than 70% of heparin. 
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Heparan sulfate is also larger than heparin, with average molecular weight ranging from 
10000 to 70000 Da.17   
Figure 3. Classes of glycans, including the proteoglycans modified with 
glycosaminoglycans: heparan, chondroitin, and dermatan sulfate9  
 
Chondroitin sulfate consists of repeating disaccharide units of sulfate substituted 
N-acetylgalactosamine and glucuronic acid polymerized into long chains (Figure 3).17  
Peak average molecular weight of pharmaceutical grade chondroitin sulfate has been 
determined to be about 20000 to 29000 Da.18 Glucosamine and chondroitin sulfate have 
been promoted to relieve symptoms of osteoarthritis, a painful condition involving the age-
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dependent erosion of articular cartilage. The primary glycans in cartilage, which provides 
a cushion between bone joints to minimize mechanical damage, are hyaluronan and 
chondroitin sulfate. A number of clinical trials have reported improvement of osteoarthritis 
symptoms and a decreased rate of joint space narrowing following treatment with 
chondroitin sulfate/glucosamine.17  
Hyaluronan is the largest polysaccharide found in vertebrates and consists of ~104 
repeating disaccharide units of N-acetylglucosamine and glucuronic acid that form 
hydrated matrices (Figure 3). Unlike other GAGs, hyaluronan is not further modified in its 
biosynthesis by sulfation or epimerization of the glucuronic acid moiety to iduronic acid. 
Hyaluronan is also the only GAG to be synthesized in the cytoplasm at the plasma 
membrane where the polymer extrudes extracellularly. Hyaluronan functions in synovial 
fluids of articular joints to distribute the load during joint motion and protect cartilaginous 
surfaces.17  
Like chondroitin sulfate, dermatan sulfate consists of repeating disaccharide units 
of sulfate substituted N-acetylgalactosamine and uronic acid, in this case primarily 
iduronic acid. Additional enzymes involved in the biosynthesis of dermatan sulfate exist 
for epimerization of glucuronic acid into iduronic acid and sulfation in patterns that are 
found only in unusual species of chondroitin.17 The average molecular weight of dermatan 
sulfate prepared from bovine intestinal mucosa is 25000 Da.19 Dermatan sulfate, like the 
other GAGs, is involved with many biological activities including coagulation, 
cardiovascular disease, tumorigenesis, infection, wound repair, and fibrosis.20 
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1.4 Polymers Approved as Drugs 
1.4.1 Heparin 
Heparin or unfractionated heparin (UFH) is a GAG that is well-known as an 
anticoagulant and is widely used to treat or prevent clotting of the blood. Blood makes up 
7-8% of total body weight and the average person has 9-12 pints of blood in the body.21 
It is obvious that health problems related to blood disorders and clotting are serious and 
have an important impact on human morbidity and mortality. Abnormal blood clots can 
lead to deep vein thrombosis (DVT), pulmonary embolism (PE), heart attack, and stroke, 
all of which can be fatal with just DVT alone resulting in 100,000 deaths annually in the 
United States.21 Heparin is highly sulfated and very negatively charged at physiological 
pH (Figure 4).6 Although found naturally in the human body, heparin for therapeutic use 
today is derived from pig intestines.  
 
Figure 4. An example of heparin polymeric GAG structure with the most common 
repeating disaccharide unit consisting of a 2-O-sulfated iduronic acid residue and a 6-O-
sulfated, N-sulfated glucosamine residue with important functional groups shown in blue.  
 
Heparin is a highly sulfated polysaccharide and its structure consists of alternating 
disaccharide units of uronic acid and hexosamine residues.22 The uronic acid component 
is predominantly L-iduronic acid in α-L-configuration and the hexosamine component is 
D-glucuronic acid, usually with N-acetylated glucosamine residues. The most common 
repeating disaccharide unit consists of a 2-O-sulfated iduronic acid residue and a 6-O-
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sulfated, N-sulfated glucosamine residue.22 Heparin’s mechanism of action for 
anticoagulation is due to its ability to bind to antithrombin and accelerate antithrombin-
mediated inhibition of coagulation factors. Heparin chains contains the antithombin-
binding region, a pentasaccahide sequence that has been rigorously studied and 
characterized (Figure 5). All sulfate groups that are essential and important for high-
affinity binding to antithombin have also been identified.22 The high affinity 
pentasaccharide sequence is expected to be present in 25-30% of chains. The average 
chain length is between 40 and 50 monomer units and the polydispersity (calculated by 
weight average molecular weight divided by number average molecular weight) is 
between 1.3 - 1.4.23 
Figure 5. The heparin pentasaccharide sequence is the key structural unit of heparin and 
is responsible for anticoagulant activity via binding to anti-thrombin with key functional 
groups shown in blue. 
Although heparin is one of the oldest drugs and was discovered a century ago, it 
took many years to move from the laboratory to the bedside. In 1922, William Henry 
Howell introduced an aqueous extraction protocol for isolating heparin but after 
commercial production, studies demonstrated that this preparation caused side effects 
including headache, fevers, and nausea.22 In 1933, Charles Best and David Scott, with 
the goal of further purification and reduction of side effects, outlined a protocol for isolating 
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a crude heparin preparation from bovine liver and purification, but the preparations were 
not pure in the chemical sense, but rather free from toxic components. However, there 
were problems getting consistent results from batch to batch which hampered clinical 
progress. By 1949, Dr. Peter Moloney and Dr. Edith Taylor had patented a method that 
obtained a greater yield of heparin at lower cost. It is noteworthy that before the exact 
nature of heparin’s component carbohydrate residues and location of sulfate groups on 
the polysaccharide chains were known, it was still successfully used in clinics as an 
anticoagulant.22 Today, many issues must be considered regarding the development and 
drug approval of heparins and heparin mimetics due to their polydisperse, heterogeneous 
nature.24  
 Heparin originates in mast cell granules as the polysaccharide part of the 
proteoglycan serglycin and upon degranulation, heparin is released from mast cells and 
broken down by heparanase into fragments that are mostly between 5000 and 30000 Da. 
Heparin used in medicine is a heterogeneous polydisperse mixture containing chains 
from under 5000 Da to over 50000 Da.25 The U.S. Pharmacopeia Convention provides 
acceptable ranges for the molecular weight distribution of heparin sodium indicating that 
molecular weights above 24000 Da should represent no more than 20% of the sample, 
the weight average molecular weight should be between 15000-19000 Da, and the ratio 
of chains between 8000-16000 and 16000-24000 should be no less than 1.0.26  
 In 2008 Baxter Healthcare had to recall its heparin sodium for injection after acute 
hypersensitivity reactions developed in patients receiving the drug and 81 deaths 
involving at least one symptom of an allergic reaction or hypotension were reported. 
There was a contaminant in the heparin that led to this fatal outcome, identified as over-
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sulfated chondroitin sulfate (OSCS) that represented almost 30% by weight/weight in the 
suspect heparin. OSCS that contains four sulfates per disaccharide unit is structurally 
similar to heparin, but OSCS can directly activate the coagulation contact system, induce 
the generation of anaphylatoxins in vitro, and activate kallikrein (which leads to profound 
hypotension in pig models). Major efforts have been underway since the notorious 
contaminated heparin issue came to light by researchers to develop screening an testing 
procedures to detect polysulfated contaminants in heparin that may have unintended 
pharmacologic consequences.27 
Heparin possesses a myriad of biological activities, the most well known being 
anticoagulation through the activation of antithrombin to inhibit clot formation. Heparin 
also plays a role in proliferation by activating growth factors to induce cell growth, 
differentiation, and morphogenesis. Heparin can bind to chemokines to modulate 
inflammation and wound healing. Heparin also binds to enveloped virus glycoproteins to 
modulate infection of target cells. Heparin is amongst the World Health Organization’s 
Model List of Essential Medicines, but is associated with certain side effects that may limit 
its use.28 Excess bleeding is a serious concern, although there is an antidote to heparin 
available: protamine sulfate, which functions to reduce heparin’s blood thinning capability 
by binding to it through electrostatic attraction and ionic bonding. Heparin-induced 
thrombocytopenia (HIT) is an immune reaction that causes a drop in platelet count and 
occurs in 3.5% of treated patients.4 Further, the polydisperse, heterogeneous nature of 
heparin can cause variable patient response.5 Because of the omnipresent need for 
anticoagulant therapies and the drawbacks associated with heparin use, developing 
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alternative medications that target coagulation is an important goal for biomedical 
researchers.5-8 
 1.4.1.1 Heparin’s Use in the Lung 
 Although heparin is primarily used as an anticoagulant, off-label use of inhaled 
heparin and other anticoagulants has occurred in the treatment of asthma, acute lung 
injury, and inhalational lung injury.29-37 This is because the inflammation pathways 
associated with asthma are linked with coagulation pathways and microvascular thrombi 
and alveolar fibrin depositions occur in acute lung injury.31,36 There is crosstalk between 
inflammation and coagulation when plasma containing clotting factors leaks from lung 
capillaries due to inflammation. Further, fibrin deposits are increased by the decrease in 
activity of the anticoagulant protein C system and inhibition of fibrinolysis (Figure 6). 
Fondaparinux, hirudin, tissue plasminogen activator (tPA), and urokinase-type 
plasminogen activator (uPA) have been shown to improve the disturbed hemostatic 
balance in the lung, thereby diminishing allergic inflammation and asthma parameters 
(Figure 7).36  
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Figure 7. Fondaparinux inhibits factor Xa, hirudin inhbits thrombin, and tPA/uPA activate 
plasminogen to improve the hemostatic balance in the lung and decrease inflammation 
associated with asthma.32 
 
Figure 6. Inflammation and coagulation pathway crosstalk in the lung32 
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Acute lung injury is characterized by activated coagulation that may initiate or 
exaggerate the injury, impair alveolar aeration and perfusion, and promote fibrosis. Acute 
lung injury is also associated with attenuated fibrinolysis and enhanced breakdown and 
decreased production of endogenous anticoagulants. The use of systemic anticoagulants 
in acute lung injury has shown inconsistent results in clinical trials:  
 The PROWESS (Protein C Worldwide Evaluation in Severe Sepsis) trial 
showed that patients with a pulmonary cause of sepsis benefited more from 
anticoagulation with recombinant human activated protein C (rh-APC) than 
patients with sepsis caused by another source. 
 The CAPTIVATE (Community-Acquired Pneumonia Tifacogin Intra-Venous 
Administration Trial for Efficacy) study suggested that infusion of 
recombinant human tissue factor pathway inhibitor (rh-TFPI) improved 
survival of patients with community-acquired pneumonia (CAP) but failed to 
improve outcomes of patients with severe CAP. 
However, higher lung concentrations may be necessary to have the desired effect on 
pulmonary coagulation than is achievable with systemic administration. The risk of 
bleeding increases with high systemic doses and there is questionable lung penetration 
of anticoagulants administered systemically, providing support for direct, local 
administration to the lung.31 A Phase 1 trial of nebulized heparin in acute lung injury 
involving 16 ventilated patients showed that administration of nebulized heparin was 
feasible and not associated with any serious adverse events, although higher doses did 
increase activated partial thromboplastin time (APTT).35 
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 The benefits of heparin in treating inhalational lung injury have been shown in 
multiple studies.29 Nebulized heparin with N-acetylcysteine has been shown to reduce 
tracheobronchial cast formation and lung edema associated with inhalational lung injury 
as well as decrease reintubation rates, the incidence of atelectasis (lung collapse), and 
mortality in pediatric burn patients. In a retrospective trial of 52 patients on mechanical 
ventilation vs. 11 control patients in Singapore, treatment with nebulized heparin, N-
acetylcysteine, and salbutamol was found to be safe in that APTT, partial thromboplastin 
time (PT), and platelet counts followed the same trend in both groups and no significant 
increase in bleeding risk was observed for the treatment group.29 
 Although the potentially beneficial effect of inhaled heparin in experimental models 
of acute lung injury has not yet been fully translated into clinical practice, the extensive 
crosstalk between coagulation and inflammation suggests that targeting pulmonary 
coagulopathy may influence the local inflammatory response. Preclinical studies provide 
some evidence of the benefits of heparin delivered by inhalation in several animal models, 
but clinical investigations in humans are sparse.32 More clinical trials are necessary to 
evaluate the clinical utility of inhaled heparin and address what doses can achieve 
maximal local effects without the risk of systemic complications, what should be the 
duration of therapy, and if the underlying cause of the lung injury plays a role.32 
1.4.2 Low Molecular Weight Heparins  
 
Low molecular weight heparins (LMWHs) have now largely replaced UFH because 
they produce a much more predictable anticoagulant response and are at least as 
effective and as safe as UFH. 24 The FDA stipulates that each LMWH is unique and they 
are not interchangeable due to significant structural, pharmacological, and toxicological 
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differences. Five criteria are used to determine similarity or difference among LMWHs: 
physicochemical characteristics, source of UFH, structural composition, in vitro biological 
activity, and in vivo pharmacodynamics profile.4 Because LMWH have high bioavailability 
after subcutaneous (SC) injection, LMWH’s dose can be calculated based on body weight 
and given SC without monitoring or dose adjustment.24 The class of LMWHs includes: 
dalteparin (Figure 8), enoxaparin (Figure 9), tinzaparin (Figure 10), and nadroparin (not 
available in the United States).1   
Although LMWHs are all derived from heparin and share a similar mechanism of 
action, their molecular weight distributions are approximately one-third that of UFH and 
vary from each other, resulting in differences in their activity against clotting enzymes 
factor Xa and thrombin (factor IIa), their affinity for plasma proteins, and their half-lives. 
LMWHs are distinct pharmacologic entities and have different properties such as: method 
of preparation, molecular structure, half-lives, antithrombin and non-antithrombin 
mediated activity, effect on thrombus, and dosing interval.1 FDA-approved indications for 
these agents are product specific and have been evaluated extensively for a wide array 
of indications such as acute coronary syndromes, DVT, PE, and prevention of venous 
thromboembolism in high-risk populations.1  
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Figure 8. Structure of dalteparin, showing anhydromannose in blue that is formed as a 
result of the nitrous acid depolymerization in dalteparin’s production from unfractionated 
heparin1  
 
 
Figure 9. Structure of enoxaparin, showing the double bond in blue produced from the 
benzylation and alkaline depolymerization used in production1 
 
 
Figure 10. Structure of tinzaparin, showing the double bond in blue introduced from the 
enzymatic depolymerization with heparinase used in production1 
 
Three different depolymerization processes of porcine mucosal pharmaceutical 
grade heparin preparations induce distinct changes to the heparin molecule, which results 
in the unique molecular structure of each LMWH. The nitrous acid depolymerization used 
to produce dalteparin induces the formation of anhydromannose. Benzylation followed by 
alkaline depolymerization is used to produce enoxaparin and introduces a double bond. 
Tinzaparin is made through enzymatic depolymerization with heparinase, which also 
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introduces a double bond. Each preparation has different proportions of the antithrombin-
binding region (Figure 5) and linkage regions.1 Enoxaparin, for example, has a peak 
average molecular weight of 4500 Da and polydispersity (weight average molecular 
weight divided by number average molecular weight) between 1.1 and 1.5. Chains range 
in length from 2 to 32 monomer units and fingerprints of 2 to 12 monomer unit long chains 
account for 70 – 80% of the sample (with a peak average molecular weight of this portion 
being 3600 Da). The high affinity pentasaccharide sequence is present in 15 to 25% of 
chains in the sample. Enoxaparin contains odd and even chains and a specific proportion 
of 8 known disaccharides.4  
1.4.3 Fondaparinux 
Another drug related to heparins is fondaparinux, which is not a heterogeneous 
mixture like the others, but a single chemical entity consisting of solely of the 
pentasaccharide sequence responsible for activity in the other heparins, with an O-methyl 
group at the reducing end which prevents side reactions during synthesis (Figure 11). 
Fondaparinux can be considered an ultralow molecular weight heparin and has a 
molecular weight of 1728 Da, has no anti-thrombin activity, and is a specific factor Xa 
inhibitor.38 Fondaparinux was first synthesized in 1986, but the preparation involves long 
and complex chemical synthesis, making it expensive.38,39 
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Figure 11. Structure of fondaparinux39 
 
1.4.4 Pentosan Polysulfate Sodium (PPS) 
 Chemically and structurally related to GAGs, a heparin-like macromolecular 
carbohydrate derivative known as pentosan polysulfate sodium (PPS), which has 
anticoagulant and fibrinolytic effects, has been approved by the FDA (Figure 12).2 PPS is 
indicated for the relief of bladder pain and discomfort associated with interstitial cystitis. 
Although the mechanism of action is unknown, PPS has been shown to adhere to the 
bladder wall mucosal membrane and may act as a buffer to control cell permeability and 
prevent irritating solutes in urine from reaching cells.2 PPS is chemically known as β-D-
xylan, (1-4), 2, 3-bis (hydrogen sulfate) sodium and is a mixture of linear polymers of β-1 
to 4 linked xylopyranose, usually sulfated at the 2- and 3-positions and occasionally 
substituted at the 2-position with 4-O-methyl-α-D-glucuronic acid 2, 3-O-sulfate. As a 
requirement of the FDA, PPS should have a capillary electrophoresis pattern identical to 
the low molecular weight distribution pattern of the innovator’s product (tradename: 
Elmiron®).40 The highly reproducible fingerprint was achieved using a benzene-1,2,4-
tricarboxylic acid buffer (8.75 mM, pH 4.9) with indirect UV detection at 217nm (Figure 
13).41 PPS used clinically in humans is confined to material manufactured by one 
company, but there are three manufacturers of PPS for veterinary applications.41  
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Figure 12. Pentosan Polysulfate structure  
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Fractions of pentosan polysulfate with higher degrees of sulfation are thought to 
have better efficacy than less sulfated fractions, however, it is difficult to achieve high 
levels of sulfation at consistent positions on the chain in low molecular weight ranges. 
The degree of sulfation within known formulations can vary widely, which may lead to 
variability in clinical efficacy.40 The number of xylose units in a PPS mixture can range 
from 6 to 30 with on average a 4-O-methyl-D-glucuronic acid randomly attached every 8 
 Figure 13.  Capillary  electropherogram  of  three  batches  (A,  B,  C)  from  one 
manufacturer of pentosan polysulfate using a benzene-1,2,4-tricarboxylic acid buffer 
(8.75 mM, pH 4.9) with indirect UV detection at 217nm41  
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to 10 xylose units and typically contain 15 to 17% sulfation.40,41 PPS is synthesized from 
xylan extracted from the bark of beech trees and other plants, which is then treated with 
sulfating agents followed by sodium hydroxide to yield the sodium salt. Differences in the 
manufacturing process can result in molecular differences of PPS mixtures, such as the 
degree and position of sulfate groups.40,41 Clinical efficacy of sulfated carbohydrates is 
well known to be affected by the type and position of sulfate groups, thereby showing the 
need to fully control and characterize these molecules.40 Drug registration authorities 
insist that drug manufacturers provide analytical evidence of the molecular weights and 
structural identity of active ingredients used in their preparations and that these criteria 
remain consistent from batch to batch.41  
 
1.5 Polymers that are Potential Drug Candidates 
1.5.1 Semuloparin 
A new class of heparins called ultra-low molecular weight heparins (ULMWHs) contains 
the experimental drug semuloparin that has an average molecular mass of 2000 to 3000 
Da. It is made up of oligosaccharides containing 1 to 11 heparin disaccharide subunits 
with an average length of 8 subunits (Figure 14 
Figure 14).  The amino sugars of the oligosaccharides can be N-sulfated or N-
acetylated and both the hexuronic acid (which is mainly iduronic acid) and the 
glucosamine moieties can have O-sulfate groups at various positions. Most of the 
molecules will have a double bond at the non-reducing end of the chain. Drug developers 
looked carefully at attributes and liabilities of existing LMWHs with the goal of advancing 
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the class to the next level and provide an optimized efficacy-bleeding balance for 
semuloparin when compared with LMWHs.42   
Semuloparin is generated using novel and proprietary manufacturing processes 
with highly selective polymerization of heparin by the phosphazene base. Throughout this 
process, anithrombin-binding sites significant for anticoagulant activity are protected from 
destruction, and a distinct composition of the oligosaccharide chains with significantly 
reduced average molecular weight of 2400 Da (compared with 3500 to 6000 Da for 
LMWHs) can be obtained. The different structural features translate to a unique 
anticoagulant and pharmacokinetic profile when compared with the LMWH class.42 
 Semuloparin has been studied in a Phase 3 clinical trial for prevention of venous 
thromboembolism (VTE) in major abdominal surgery, but was not able to demonstrate 
non-inferiority to enoxaparin.43 However, the pivotal SAVE-ONCO trial found that 
semuloparin reduced the incidence of VTE in chemotherapy patients and did not cause 
an increase in major bleeding versus placebo.44 Unfortunately, in June of 2012 the 
Oncologic Drugs Advisory Committee to the FDA was concerned that the results of the 
SAVE-ONCO trial may not be clinically meaningful and questioned the study protocol 
design. Ultimately, they voted almost unanimously against approval of semuloparin for 
prophylactic prevention of VTE in cancer patients undergoing chemotherapy.45 By July of 
the same year, semuloparin’s manufacturer withdrew the drug application and announced 
that they would no longer seek marketing approval.46 
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Figure 14. Structure of semuloparin 
 
1.5.2 2-O, 3-O-Desulfated Heparin (ODSH) 
Another therapeutically useful compound derived from heparin is 2-O, 3-O-
desulfated heparin (ODSH).47-50 It is synthesized from USP porcine intestinal heparin by 
cold alkaline hydrolysis, which removes the 2-O sulfate groups from iduronic acid 
residues and the 3-O sulfate groups from the glucosamine residues of heparin. The N-
sulfates, 6-O sulfates, and carboxylates on the heparin backbone remain intact (Figure 
15).47 ODSH has low anticoagulant activity and broad anti-inflammatory activity, 
demonstrating that most of the anti-inflammatory pharmacology of heparin is unrelated to 
anticoagulant activity and the 2-O and 3-O sulfate groups can be removed to reduce 
anticoagulant activity of heparin without impairing its anti-inflammatory abilities. Like 
heparin, ODSH inhibits complement activation, binding to the leukocyte adhesion 
molecule P-selectin, and the leukocyte cationic granular proteins azurocidin, human 
leukocyte elastase (HLE), and cathepsin G.48 Heparin and ODSH disrupt Mac-
1(CD11b/CD18)-mediated leukocyte adhesion to the receptor for advanced glycation end 
products (RAGE) and inhibit ligation of RAGE by its many proinflammatory ligands, 
including the advanced glycation end-product carboxymethyl lysine-bovine serum 
albumin, the nuclear protein high mobility group box protein-1 (HMGB-1), and S100 
calgranulins. ODSH has been found to be more effective than heparin in mice studies in 
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reducing selectin-mediated lung metastasis from melanoma and inhibits RAGE-mediated 
airway inflammation from intratracheal HMGB-1.48Figure 15. ODSH (2-O, 3-O desulfated 
heparin) structure 
 
A phase II study evaluating ODSH in subjects with chronic obstructive pulmonary 
disease (COPD) exacerbations was terminated in 2012 due to results showing evidence 
of safety without efficacy. It was thought that because ODSH is a potent inhibitor of 
cationic neutrophil proteases HLE and cathepsin G and inhibits the interactions 
leukocytes with endothelium by inhibiting the attachment molecule P-selectin, it would 
prevent neutrophil accumulation in areas of inflammation and be beneficial for treating 
COPD exacerbations. Management of acute COPD exacerbations are treated the same 
as they were for the past 40 years with bronchodilators, corticosteroids, and antibiotics. 
Neutrophils play a prominent pathophysiological role in COPD exacerbations, so they and 
their toxic oxidants and proteases represent previously unchallenged therapeutic targets. 
Therefore, blocking neutrophilic influx from the vascular space into the airway and 
neutralizing toxins such as HLE and cathepsin G would disrupt neutrophilic airway 
inflammation and be a possible mechanism for ODSH to mediate COPD exacerbations.51  
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1.5.3 Phosphomannopentose Sulfate (PI-88) 
Another drug candidate that is a heparan sulfate mimetic is a sulfated 
oligosaccharide known as phosphomannopentose sulfate (PI-88).3 It is derived from 
hydrolysis of extracellular phosphomannan that is produced by the yeast Pichia holstii, 
which liberates a mixture of many oligosaccharides, and is then exhaustively sulfated.  
The multi-component mixture is composed primarily (90%) of phosphomannopentose 
and phosphomannotetrose sulfates, with the ratio between penta:tertra ranging from 2:1 
to 3:2 (Figure 16). Di-, tri-, and hexa-phosphomannosulfates and a phosphotetrasaccharyl 
amine compound are also present in PI-88 preparations. Sulfation of the mixture of 
oligosaccharides does not go to completion, which results in a random, but reproducible, 
mixture of sulfated oligosaccharides with the average degree of sulfation per mannose 
unit ranging from 2.9 to 3.1. A comparison of properties for PPS and PI-88 including 
ranges of average molecular weight is provided above (Table 1).3 
  
27 
 
Figure 16. Structure of PI-88, which is predominantly composed (90%) of 
phosphomannopentose (n=2) and phosphomannotetrose (n=1) sulfates in a ratio of 
penta:tetrasaccharide ranging from 2:1 to 3:2. Average degree of sulfation ranges from 
2.9 to 3.1 per mannose unit. 
 
 
PI-88 mimics the structure of heparan sulfate and has the ability to inhibit the 
heparan sulfate cleaving enzyme known as heparanase. Heparanase has been 
implicated in tumor metastasis and recognition of cell surface heparan sulfate by 
angiogenic growth factors plays an important role in angiogenesis. In vivo studies of PI-
88 revealed its capacity to inhibit tumor growth, metastasis, and angiogenesis.3 PI-88 is 
currently in a Phase 3 clinical trial for adjuvant treatment of patients with hepatitis related 
liver cancer after surgical resection.52 In 2007, the FDA awarded Fast Track status to PI-
88 for the prevention of tumor recurrence following liver resection in patients with 
hepatocellular carcinoma.53 
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Table 1. Comparison of properties of heparin, LMWHs, fondaparinux, PPS, semuloparin, 
ODSH, and PI-88. 
Drug 
Method of 
Preparation 
Molecular Weight 
(Daltons) 
Half-
Life 
(min) 
Anti-Xa: 
Anti-IIa 
Activity 
Ratio 
Heparin (UFH) 
purified from 
porcine intestinal 
mucosa 
Peak Average: 16371 
Number Average: 13537 
Weight Average: 1800026 
60-9054 1.0426 
Dalteparin 
Nitrous acid 
depolymerization
1 
Mean: 60001 
<3000: 3-15% 
3000-8000: 65-78% 
>8000: 14-26%55 
119-
1391 
2.71 
Enoxaparin 
Benzylation and 
alkaline 
depolymerization
1 
Mean: 42001; 450056 
<2000: 12-20% (16% avg) 
2000-8000: 68-82% (74% 
avg) 
>8000: ≤18%56 
129-
1801 
3.81 
Tinzaparin 
Heparinase 
digestion1 
Mean: 45001 
<2000: <10% 
2000-8000: 60-72% 
>8000: 22-36%57 
111-
2341 
2.81 
Fondaparinux 
Long, complex 
synthesis with O-
methyl group at 
reducing end38 
172839 
900-
120039 
Anti-Xa 
only39 
Pentosan 
polysulfate 
sodium (PPS) 
Bark of beech 
tree; Semi-
synthetic2 
4000-60002 
1200-
16202 
Weak, 
(1/15 of 
heparin)
2 
Semuloparin 
highly selective 
polymerization of 
heparin by 
phosphazene 
base42 
Mean: 2400 
 
2000-300042 
 
960-
120042 
8042 
2-O, 3-O-
desulfated 
heparin 
(ODSH) 
cold alkaline 
hydrolysis48 
Mean: 11700 ± 30048; 
1050058 
<6000: 30% 
<10000: >60%58 
116-
16348 
low for 
either 
Phosphor-
mannopentose 
sulfate (PI-88) 
Yeast Pichia 
holstii; 
hydrolysis, 
sulfation3 
Mean: 2400 
1400-31003 
60-1623 
Strong 
fIIa 
inhibitor; 
no effect 
on fXa3 
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2. Rationale for the Development of Low Molecular Weight Lignins (LMWLs) 
As evidenced in the chapter above, developing polymers as drugs is challenging 
work, but the therapeutic utility of polymers is promising for the treatment of many disease 
states. As demonstrated for the approved polymers discussed above, it is possible to get 
a polymer approved as a drug without full knowledge of its exact structure. This is 
because structural characterization of polymers is difficult, and describing polymers’ 
molecular weight, chain length, linkage pattern, or degree of substitution with key 
functional groups takes a large amount of data to determine acceptable average ranges 
and assess similarity, not just a single value that must match. Varying degrees and depth 
of information is known about each of the polymers discussed above, and there is no set 
criteria for the evaluation of polymers stipulating what must be known before a polymer 
can be approved as a drug.  
For LMWHs, the FDA uses five criteria to describe their similarities and differences: 
source of UFH it is synthesized from, physicochemical characteristics, structural 
composition, in vitro biological activity, and in vivo pharmacodynamics profile.4 Two of 
those criteria, the biological activity and pharmacodynamics, have been reported for the 
promising polymers known as sulfated low molecular weight lignin (LMWLs), originally 
developed as heparin mimetics,  and will be summarized in this chapter. Less is known 
about two of the other criteria, structural composition and physicochemical 
characteristics, which are described in chapters 2 and 3 of this work. Determining the 
structural composition, establishing physicochemical parameters, and analyzing 
batch variability of a library of LMWLs to further their development as drugs is the 
primary goal of this work. 
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Sulfated LMWLs have shown good activity as anticoagulants, as well as promising 
agents for treating emphysema and in xenotransplantation.5-9 These dehydropolymers of 
cinnamic acid derivatives (caffeic (CA), ferulic (FA), and sinapic acid (SA) are chemo-
enzymatically synthesized as polydisperse, heterogeneous polymer mixtures of varying 
chain length, linkage, and sulfation patterns. Before sulfation, the LMWLs are abbreviated 
CD, FD, and SD based on the corresponding monomer and serve as precursors of the 
sulfated LMWLs, abbreviated in kind as CDS, FDS, and SDS. Similarities between 
heparin and sulfated LMWLs include: anticoagulant activity, polymeric structure, sulfation, 
and negative charge. However, notable differences are evident in the non-sugar, aromatic 
backbone of sulfated LMWLs vs the GAG backbone of heparin, the lesser degree of 
sulfation in LMWLs, and the 2-5 times reduced average molecular weight of LMWLs 
(3,000-6,000 Da) vs heparin (15,000 Da).5-8,59  
LMWLs are reported to have potent anticoagulant activity, primarily through 
allosteric inhibition of thrombin by binding in exosite II.5 Heparin competes with sulfated 
LMWLs for binding to clotting factors Xa and XIa.60 Sulfated LMWLs also inhibit a select 
group of heparin-binding serine proteases with measured IC50 values (Table 2).60 CDS 
was the most potent LMWL by at least a factor of 2 in inhibiting thrombin (IC50= 18 nM), 
factor Xa (IC50= 34 nM), and factor XIa (IC50= 22 nM).60  
Both unsulfated and sulfated LMWLs increase the time it takes blood to clot, 
although the latter is more potent, as measured by activated partial thromboplastin time 
(APTT) and prothrombin time (PT) clotting assays (Table 2). While all LMWLs were more 
effective at increasing PT than LMWH, LMWH was more potent than LMWLs at 
increasing APTT. Again, CDS was the most potent LMWL at increasing APTT and PT.8 
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Table 2. Concentrations of LMWLs necessary to increase the clotting time 2 times over 
baseline PT or APTT clotting time in human plasma [Adapted from Ref 24] 
 
Table 3. 50% inhibitory concentration (IC50) values measured through chromogenic 
substrate hydrolysis assays for sulfated LMWLs and heparin [Adapted from Ref. 60] 
 2 x PT (ug/mL) 2 x APTT (ug/mL) 
CD 98.1 ± 0.7 24.9 ± 2.3 
FD 161.3 ± 2.7 39.5 ± 0.8 
SD 212 ± 2.9 32.1 ± 1.5 
CDS 42.1 ± 0.3 13 ± 5 
FDS 63.4 ± 0.1 18.3 ± 1.9 
SDS 104.6 ± 3.9 22.6 ± 1.1 
LMWH 142.1 ± 3.6 5.9 ± 3 
 
Throughout this work, emphasis will be placed on the development of one LMWL 
in particular: the sulfated dehydropolymer of caffeic acid (CDS), which has been 
evaluated in animal models for the treatment of emphysema.9 CDS has shown promising 
activity for treating emphysema through in vitro inhibitory activity against elastase, 
oxidation, and inflammation.61 Emphysema is a manifestation of chronic obstructive 
Heparin-Binding 
Serine Protease 
CDS 
(nM) 
FDS 
(nM) 
SDS 
(nM) 
Heparin 
(nM) 
Cathepsin G 232 ± 10 91 ± 7 105 ± 7 42 ± 7 
Human Leukocyte 
Elastase (HLE) 
11 ± 2 9 ± 2 17 ± 1 1.1 ± 0.1 
Plasmin 240 ± 30 760 ± 20 1290 ± 60 No inhibition 
Thrombin 18 ± 2 29 ± 2 94 ± 4 No inhibition 
Factor Xa 34 ± 5 74 ± 8 121 ± 26 No inhibition 
Factor IXa 3380 ± 64 490 ± 16 >28,500 No inhibition 
Factor XIa 22 ± 2 105 ± 11 176 ± 11 No inhibition 
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pulmonary disease (COPD) which progressively destroys alveolar structures, causes 
breathing difficulty, chronic cough, physical and functional disability, and eventually - 
death.9 Bronchodilators and inhaled corticosteroids are used for management of COPD 
symptoms, but no drugs are approved for the prevention, intervention, or resolution of this 
life-threatening disease. COPD effects 13 million people and costs $50 billion annually in 
the US, where it is the third leading cause of death. The LMWL CDS is a promising, novel 
drug for the treatment of emphysema.9 
Induced proteolysis, oxidative stress, and inflammation are thought to be the major 
mechanisms that lead to emphysema, but the pathobiology of alveolar septum destruction 
and loss is not fully understood.9 Inhibition of a single mechanism can be compensated 
for by one of the other interacting mechanisms, therefore drugs that target multiple 
mechanisms are likely to be more effective at treating emphysema. CDS is a versatile, 
potent, triple-action inhibitor of induced elastolysis, oxidation, and inflammation at low 
micromolar concentrations in vitro.9 CDS exhibited in vitro anti-human neutrophil elastase 
(HNE) activity with an IC50 of 0.43 ± 0.04 µM, anti-chemical oxidative activity with an IC50 
of 3.52 ± 0.14 µM, and anti-inflammatory activity with an IC50 of ~10 µM.61 
A rat model of emphysema involves orotracheal (OT) instillation of human sputum 
elastase (HSE) and cigarette smoke extract (CSE) that induces elastolysis, oxidative 
stress, inflammation, airway luminal neutrophil infiltration, lung functional impairment of 
exercise endurance, and morphological airspace enlargement.9 CDS was administered 
in this model in both a preventative (before the HSE/CSE instillation) for acute features 
of emphysema and interventional (after the HSE/CSE instillation) fashion. CDS was found 
to inhibit induced elastolysis, oxidative stress, and inflammation and attenuate the 
33 
 
development of emphysema with a one-time dose of 30 ug/kg when administered 
between 2 hours before to 24 hours after HSE/CSE instillation. Doses of 30 ug/kg of CDS 
maintained their preventative effects in the lungs for 6 hours, whereas doses of 100 ug/kg 
were able to extend their effect to 24 hours. CDS’s duration of action of up to a day after 
pulmonary administration was likely achievable because the LMWL polymer has higher 
molecular weight that enables sustained retention in the lung due to slow absorption and 
resistance to degradation.9 
Interventional administration one week after the HSE/CSE instillation enabled 
more a clinically realistic model of CDS’s ability to limit the progression of emphysema.9 
A week after HSE/CSE instillation, CDS was dosed at 30 ug/kg every two days for three 
weeks and rats were found to be capable of maintaining ~60% healthy exercise 
endurance and airspace. This suggests that CDS can still provide effective intervention 
in the development of emphysema even when the administration occurs up to a week 
after emphysema has been induced. CDS was also administered in the rat model 
subcutaneously, but was found to be ineffective when administered by this route, 
suggesting a need for local delivery to the lung.9  
CDS’s prophylactic attenuation of elastase-induced emphysema following 
pulmonary administration in rats is also an activity exhibited by heparin.9 Heparin’s 
attenuation of emphysema is attributed to its anti-elastase activity and it is not considered 
directly anti-oxidative, whereas CDS demonstrates both inhibitory activities. CDS is much 
more potent than heparin at attenuating emphysema, with an effective molar dose of 9 
nmoles/kg versus ~200 nmoles/kg for heparin.9 
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 Although impressive and promising in vitro biological activities and in vivo 
pharmacodynamics have been reported in support of the development of LMWLs as 
drugs, there are still significant questions regarding their physicochemical characteristics 
and structural composition. Thus far, the reported molecular weights for the sulfated 
LMWLs (CDS, FDS, and SDS) were derived from GPC-HPLC analysis of their unsulfated 
LMWL precursors. This work attempts to define the structural composition of sulfated 
LMWLs directly through SEC-HPLC analysis and definition of the molecular weight 
distribution patterns. Well defined molecular weight distribution patterns are a hallmark of 
the polymer drug development process, as described for the therapeutically useful 
polymers in the introductory chapter. Not only is knowledge of the molecular weight 
distribution useful to gain drug approval, it is also necessary for calculating accurate 
doses of pharmaceuticals. Molecular dynamics simulations were conducted as part of this 
work to model the LMWLs behavior in solution.  
Another goal of this work is to describe the physicochemical properties of the 
LMWL library. Elemental analysis was performed on two batches of CDS to determine 
elemental content, batch variability, and proportion of types of linkages. Octanol-water 
distribution coefficients were measured to estimate the hydrophobicity of the LMWL 
polymers that contain a duality of features: charged functional groups and aromatic 
backbones. Determining physicochemical characteristics is another piece of the puzzle 
needed to provide a complete picture of CDS and advance its development as a drug 
candidate. The structural composition and physicochemical properties described 
in Chapter 5 for the sulfated LMWLs represents the most comprehensive and 
accurate information we have to date about how these polymers exist in reality. 
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3. Structural Characterization of LMWLs 
3.1 Background on Molecular Weight Distribution of Polymers 
 Polymers exist as repeating units of monomers bonded together in long chains 
and often as polydisperse, heterogeneous mixtures of different chain lengths, linkage 
patterns, functional group substitutions, and dynamic conformations. As such, they 
cannot be described as a single distinct chemical entity and characterizing their properties 
is more complex and prone to error than pure small molecules which commonly make up 
the active ingredient in pharmaceuticals. Molecular weights of polymers are denoted by 
distributions of chain length and acceptable percentages of the heterogeneous mixture 
must fall into similar distribution patterns to ensure minimal batch variability. Values of 
molecular weights are calculated averages from all the chain lengths in the sample and 
can be described differently: number average molecular weight (MN), weight average 
molecular weight (MW), or peak average molecular weight (MP) (Figure 17). 
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Figure 17. SEC-HPLC profile of a polymer and apparent molecular weight distribution 
estimates, highlighting the difference between peak (MP), number (MN), and weight (MW) 
average molecular weight 
 Number average molecular weight, MN, refers to the statistical average molecular 
weight of all the polymer chains, and can be calculated by: 
MN = (ƩNiMi) / (ƩNi) 
where Mi is the molecular weight of a chain and Ni is the number of chains of that 
molecular weight. There are equal numbers of molecules (N) of either side of the MN in 
the distribution. For homogeneous polymer samples, the MN is 1. 
Polymer Molecular Weight Distribution 
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 Weight average molecular weight, MW, takes into account the molecular weight of 
a chain in determining contributions to the molecular weight average. The larger the 
chain, the more it will contribute to Mw. Mw can be calculated by: 
MW = (ƩNiMi2) / ( ƩNiMi) 
where Mi is the molecular weight of a chain and Ni is the number of chains of that 
molecular weight. There is equal weight of molecules of either side of the MW in the 
distribution. 
 The peak average molecular weight, MP, represents the weight of the most 
commonly found chain in the sample and is the statistical mode of the molecular weight 
distribution. It can be calculated by determining the molecular weight corresponding to 
the maximum absorbance (top of the peak) on analytical techniques such as size 
exclusion chromatography measuring UV absorbance. 
The polydispersity index measures the broadness of the molecular weight 
distribution or the heterogeneity of a mixture and is calculated by: 
Polydisperisity index = MW / MN 
Larger polydispersity indexes correspond to broader molecular weight distribution ranges. 
Monodisperse polymers with all chain lengths in the sample being equal have a 
polydispersity of 1.62 In 2009, the International Union of Pure and Applied Chemistry 
(IUPAC) issued recommendations replace the term monodisperse with “uniform” and 
polydisperse with “non-uniform.” Further, they suggest replacing the polydispersity index 
with the new term “dispersity,” coined to denote the measure of dispersion of 
macromolecular species in a sample of polymer.63 
38 
 
Developing polymers as drugs requires setting standard distributions of molecular 
weight to ensure equivalency from batch to batch and manufacturer to manufacturer. 
Acceptable reference ranges for other properties, such as dispersity, must also be 
established for comparison. While drug approval of polymers may require more difficult 
and detailed characterization than small molecules, the success of the polymeric drugs 
discussed above illustrates the utility of developing polymers as pharmaceuticals. 
3.2 Previous SEC-HPLC Studies on Unsulfated LMWLs 
Thus far, the reported molecular weights for the sulfated LMWLs (CDS, FDS, and 
SDS) were derived from SEC-HPLC analysis of their unsulfated LMWL precursors (CD, 
FD, and SD) (Table 4). Elemental analysis was used to determine the degree of sulfation 
of CDS, FDS, and SDS, and the apparent molecular weights of CD, FD, and SD were 
combined with the sulfur content from elemental analysis to estimate the molecular weight 
of the sulfated LMWLs. The work in this thesis is the first effort to measure the sulfated 
LMWLs molecular weight distribution profile directly on SEC-HPLC, rather than derive the 
molecular weight from the unsulfated precursors.   
Table 4. Literature values of molecular weight reported for LMWLs and control 
anticoagulants 
 Reported Avg MW 
CDS 33205 
FDS 41205 
SDS 35505 
CD 28008 
FD 36508 
SD 29908 
Heparin 12000 - 15000 (13000)5 
Enoxaparin 
4500 
<2000 daltons ≤20% 
2000 to 8000 daltons ≥68% 
>8000 daltons ≤18%56 
Fondaparinux 172839 
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Because both LMWLs and heparin have complex structures (polydisperse, 
heterogeneous mixtures) their physicochemical behavior and molecular weight are 
difficult to predict and measure. However, characterizing these polymers is important to 
ensure minimal batch-to-batch variability, calculate accurate doses, and achieve 
consistent, predictable patient responses. It is the goal of this work to develop methods 
to better characterize sulfated LMWLs, such as determining the proper conditions to get 
the most accurate data from size-exclusion chromatography (SEC) performed on a high-
pressure liquid chromatography (HPLC) system. 
3.3 Synthesis 
The dehydrogenation polymers of cinnamic acid derivatives: caffeic acid (CA), 
ferulic acid (FA), and sinapic acid (SA) 
were synthesized by the “zutropfverfahren” 
procedure as described previously in 
literature to form the LMWLs.8  Briefly, 
200mL of 25mM cinnamic acid derivative 
and 100mL of 75mM hydrogen peroxide 
were added dropwise, slowly into a three 
neck round bottom flask in dark containing 
a solution of 10mg horseradish peroxidase 
(HRP) in 50mL of buffer with stirring. The 
buffer used in all cases was 10mM sodium 
phosphate, pH 8.0 and the reaction was 
performed at room temperature (25°C). 
Figure 18. Glassware set up of LMWL 
synthesis procedure 
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Three addition aliquots of 75mM hydrogen peroxide were added dropwise over the next 
72 hours at the rate of ~1 aliquot per day (Figure 18). At the end of approximately 80 
hours, the solution was freeze dried, redissolved in high purity water, and filtered 
repeatedly by centrifugation through molecular weight cut off filters of 5000 Da to remove 
salts and low molecular weight species. The final solution was washed with ether and 
freeze dried, resulting in a dark brown powder.8  
This sodium salt of each dehydropolymer was then sulfated with trimethylamine-
sulfur trioxide complex by dissolving 500mg of the dehydropolymer in 50mL 
dimethylformamide (DMF) with 1 gram of trimethylamine-sulfur trioxide complex and 
stirring for 24 hours at 60°C. DMF was then removed in vacuo and the remaining product 
taken up in 30% aqueous sodium acetate. The sodium salt was then precipitated using 
~10 volumes of cold ethanol and the precipitate was further purified by repeated filtration 
by centrifugation through molecular weight cut off filters of 10000 Da and freeze dried to 
yield a dark brown powder of the sulfated LMWLs.8 
The oxidative polymerization mechanism of the LMWL synthesis includes a 
transitional state of unstable radicals (I, II, III, IV) that combine to form the variety of 
linkages between monomers in the final product (Figure 19). For example, radicals I and 
II combine into a β-O-4 linked dimer ( Figure 20), radicals II and IV combine resulting in 
a β-5 linkage (Figure 21), and radical IV can react with itself to form a β-β linkage. 5-5 
and 5-O-4 linked monomers are also possible, but the β-O-4 and β-5 linkages are thought 
to predominate in the final product.8 
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Figure 19. Schematic of radical polymerization of caffeic acid and radical transition state 
that results in varying linkage pattern characteristic of LMWLs 
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 Figure 20. Radicals I and IV combining into β-O-4 linked dimer 
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Figure 21. Radicals II and IV combining into β-5 linked dimer 
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3.4 Size Exclusion Chromatography of LMWLs 
 SEC-HPLC is a powerful tool for the separation, identification, and quantification 
of species in a mixture. The system works by pumps that send pressurized liquid solvent 
with the sample through a column packed with porous beads made of an adsorbent 
material. Each component in the sample mixture interacts with the adsorbent material 
differently, resulting in varied elution times and allowing separation. A schematic of an 
HPLC system is provided showing the flow of the degassed mobile phase from its 
reservoir by the pumps to the autosampler where analyte is injected through the column 
into the detector and the graph output on the computer (Figure 22).64 On our Shimadzu 
HPLC system an ultra-violet (UV) SPD-10AVP detector was used and absorbance 
monitored at 206 and 280 nm.  
Figure 22. Schematic diagram of high-pressure liquid chromatography system 
Larger molecular weight species are able to flow through the column without 
getting caught in pores and elute faster than smaller molecular weight species. Smaller 
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molecular weight species can get into the pores of the packing material in the column 
resulting in a longer path length and increased time to elution. The elution volume is 
calculated by multiplying the flow rate by the time of elution and separates the mixture 
according to molecular weight and can be used to identify the species in a mixture. The 
height of the peak indicates the concentration or quantity of species in the sample.64 
A library of LMWLs was analyzed by SEC-HPLC along with control polymers 
heparin and enoxaparin (a low molecular weight heparin; LMWH) to determine number, 
weight, and peak average molecular weight and polydispersity. Both sulfated and 
unsulfated polymers were tested from 3 starting monomer acids: caffeic acid (CDS – 
sulfated; CD – unsulfated), ferulic acid (FDS; FD), and sinapic acid (SDS; SD). Three 
independently prepared batches of both CDS (CDSMT1; CDSMT2; CDSBH) and FDS 
(FDSMT, FDSJT, FDSBH) were also analyzed to determine batch variability.  
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3.4.1 Method Development 
SEC-HPLC studies began on a Shodex Asahipak GS-HQ520 column, which 
resulted in elution order of the polystyrene sulfonate (PSS) standards that violated the 
principle of SEC-HPLC columns (Table 5). A new Shodex Asahipak GS-HQ320 column 
was purchased with a Pullulan cut-off limit of 40,000, >19,000 theoretical plates, 6 micron 
particle size, 30 cm in length, and a minimum pore 
size of 400.65 The polystyrene sulfonate (PSS) 
standards that were used had molecular weights of 
208, 4230, 6530, 13200, 14900, and 32900 (Figure 
23). However, the 208 molecular weight (MW) PSS 
standard was below the maximum pore size of 400 
and was found to have varied elution volumes and 
due to this was not included in the calibration curve 
calculations. Fondaparinux was also used as a 
control in initial studies but found to have non-
reproducible elution volume, likely due to its small molecular weight of 1728 g/mol not 
being that much larger than the maximum pore size of 400. 
  
 
Figure 23. Structure of 
polystyrene sulfonate standards 
used for SEC-HPLC calibration 
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Table 5. Attempted solvents for mobile phase in SEC-HPLC studies 
 
 
Figure 24. SEC-HPLC profiles showing dual peaks of polystyrene sulfonate (PSS) 
standard of 13200 Da, as well as inconsistent results for two batches of CDS. Mobile 
phase used was 50:50 water: ethanol at 0.5mL/min and data was acquired on a 
GSHQ520 column 
Attempted Solvent for Mobile Phase of CDSO3 SEC-HPLC with GS-HQ520 
Column 
Components Flow Rate Results 
70:30 0.1 M 
NaCl in H2O: 
ACN 
0.75mL/min No peaks/too broad 
PSS does not come 
out in order that 
adheres to principle 
of SEC columns 
(Figure 25) 
50:50 
water:ethanol 
0.5mL/min 
Dual peaks of PSS, non-
reproducible sample peaks 
(Figure 24Error! Not a valid 
bookmark self-reference.) 
70:30 
water:ethanol 
0.4mL/min Broad/dual peaks 
0.1 M NaCl in 
H2O 
0.5mL/min No peaks/too broad 
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Figure 25. PSS standards coming out in order that defies the principle of SEC with the 
largest standard of 32900 Da eluting last & the 6530 Da standard eluting after the 13200 
Da & 14900 Da standards. Acquired on GSHQ520 column and 0.5mL/min water as 
mobile phase. 
The known molecular weight standards elute at measurable volumes and create a 
calibration curve that can be used to calculate unknown molecular weights based on their 
elution volume measured on the same system with the same mobile phase. The unknown 
molecular weight samples appear as a peak and the molecular weight can be calculated 
based on the elution volume at each absorbance point. These molecular weights at each 
point can then be averaged over relevant ranges to describe the molecular weight 
distribution profile.  
A PSS standard of MW below that of the predicted MW of the LMWLs would have 
increased the validity of the calibration curve in the range of the LMWLs, but with the 
elimination of the 208 MW PSS standard due to column constraints, 4230 was the next 
smallest available. Due to the structure of the PSS standards containing an aromatic 
backbone, it is likely that they are a better representation of our sulfated LMWL molecules 
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which share the aromatic backbone feature and a less similar representation of heparins 
that have a different polysaccharide backbone. This could indicate that the calculated 
molecular weights of the sulfated LMWLs is arguably more accurate than the calculated 
molecular weights of heparins tested. Previous studies had calculated the molecular 
weight of the sulfated LMWLs based on extrapolation of SEC-HPLC results from the 
unsulfated LMWLs coupled with elemental analysis of the sulfated LMWLs: CDS – 3320 
g/mol; FDS – 4120 g/mol; SDS – 3550 g/mol; CD – 2800 g/mol; FD – 3650 g/mol; SD – 
2990 g/mol.5,8  
 Because of the overestimation of the molecular weights across the board with all 
polymers and due to the known possibility of hydrophobic interactions, we hypothesized 
that aggregation was likely occurring in the LMWL samples and resulting in falsely 
elevated apparent molecular weights. The pH of the mobile phase was increased to 11 
because the basicity would result in negatively charged carboxylic acids groups on the 
polymers that in theory would cause electrostatic repulsion between polymer chains and 
reduce their tendency to aggregate. Additionally, sodium chloride salt was included in the 
mobile phase to disrupt ionic interactions between the polymers and reduce aggregation 
due to the presence of sodium and chloride ions. Finally, the addition of two different 
surfactants, Tween 80 and Triton x-100, was employed to disrupt aggregation (Figure 
26). Three concentrations of Tween 80 were utilized to detect differences in polymer 
behavior across a range of surfactant concentration. 
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Figure 26. The chemical structures of Tween 80 and Triton X-100, which are 
polydisperse, heterogeneous non-ionic surfactants 
  
To assure that the chromatography was performed under dilute conditions, a range 
of concentrations of heparin and CDS were analyzed on the HPLC system with and 
without 0.02% Tween 80 in the mobile phase. Maximum absorbance was plotted vs the 
known concentrations to get a standard curve used to back calculate the concentration 
of polymer in SEC-HPLC studies (Figure 23). Concentrations for CDS: 50, 100, 200, 400, 
1000, 3000 uM and Heparin: 50, 100, 200, 400, 700, 1000 nM. Calibration curves based 
on the known concentrations of CDS and heparin measured on our SEC-HPLC system 
are presented in Figure 27. 
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Known Concentrations of CDS and Heparin – Calibration Curves 
  
  
Figure 27. Known concentrations of CDS and Heparin calibration curves used for SEC-
HPLC 
Calculations revealed that there were 255 moles of tween per mole of heparin in 
the SEC-HPLC study with 0.02% tween 80 in the mobile phase. In contrast, there were 9 
moles of CDS per mole of tween in the same experiment. While CDS chromatography 
was therefore known to have been performed under dilute conditions whereas heparin 
was not, possible explanation for the overestimation of the molecular weight of heparin 
revealed in the study could be due to hydrogen bonding interactions between tween and 
a chain of heparin. If several (up to 255) tween molecules were associated with heparin, 
the apparent molecular weight of heparin could be increased by a factor of the molecular 
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weight of tween (1310 g/mol). For instance, the literature indicates the average molecular 
weight of heparin is 15,000 g/mol. In our study, without surfactant the MW of heparin was 
calculated to be 18,976g and with 0.02% tween 80 was 29,516g. We can then attempt to 
attribute the difference to the presence of tween by: 29,516g – 18,976g = 10,540g. 
10,540g / (1310 g/mol tween) = 8 moles of tween associated with heparin causing it to 
have a 2x overestimated (29,516g/mol) MW when 0.02% tween is used in mobile phase. 
The HPLC conditions required the use of a higher concentration of heparin than CDS 
because CDS contains aromatic groups that can be monitored at 232 – 280 nm 
wavelength whereas heparin does not contain aromatic groups. Heparin absorbance was 
monitored at 206 nm due to its lack of structural characteristics that would absorb at a 
higher wavelength, and monitoring at 206 nm can be subject to interference from a variety 
of species. Although dilute conditions are ideal in SEC-HPLC studies, a higher 
concentration of heparin is needed to achieve adequate absorbance signal on the HPLC. 
Calibration curves for all five mobile phases were established individually with 
polystyrene sulfonate standards of known molecular weights (Figure 28). The change in 
elution volumes from around 6-7mL for molecular weight species of ~3000-4000 g/mol, 
to 12-13mL is due to the experiments being performed on different days where back 
pressure in the pump can differ. Because PSS standards were shot in triplicate for each 
experiment and mobile phase, comparable calculated molecular weights were able to be 
ascertained and the differing scales of the x-axes in (Figure 28) was accounted for and 
did not affect the data analysis. Elution volumes can change over the life of a column due 
to differing pressure generated by the pumps and changes in the actual flow rate 
responsible for sending the liquid mobile phase through the system. Drifting retention 
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times may also be due to equilibration issues in the column, as retention times are 
susceptible to the amount of water adsorbed in the silica surface of the column packing 
material.66  
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SEC-HPLC Calibration Curves of Polystyrene Sulfonate Standards (PSS) 
without Surfactant 0.01% Tween 80 
  
0.02% Trition X-100 0.02% Tween 80 
 
 
0.05% Tween 80 
 
Figure 28. SEC-HPLC Calibration Curves Polystyrene Sulfonate Standards (PSS) of 
known molecular weight in various mobile phases used to calculate unknown molecular 
weight of library of LMWLs 
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3.4.2 SEC-HPLC Results and Discussion 
Chromatograms, calculated peak average molecular weight (MP), number average 
molecular weight (MN), weight average molecular weight (MW), polydispersity, and 
molecular weight distribution for the sulfated LMWLs (CDS, FDS, and SDS), the 
unsulfated LMWLs (CD, FD, and SD), and control anticoagulants (heparin and 
enoxaparin) are presented below. Average SEC-HPLC profiles were acquired using four 
mobile phases of increasing concentrations of the surfactant Tween 80 (0-0.05%). 
Molecular weight distributions were calculated for chains under 6000 Da, between 6000 
and 10000 Da, and above 10000 Da. While the 6000-10000 Da division was calculated 
for all molecules to allow for comparison, more appropriate ranges were calculated in 
addition for larger (heparin) and smaller (enoxaparin and SDS) when warranted. 
3.4.2.1 CDS and Control Anticoagulants 
  Firstly, CDS, heparin, and enoxaparin will be discussed together for comparison 
and insight into these analogous polymers’ contrasting (heparin and CDS) and 
comparable (enoxaparin and CDS) behavior in solution. 
 CDS had a bimodal molecular weight distribution pattern when no surfactant was 
used in the mobile phase (Figure 29). The MP of 9121 Da calculated from the PSS 
standard curve without surfactant is almost three times greater than the previously 
reported molecular weight for CDS of 3320 Da (Table 6). There is a second MP of ~23000 
Da visible in the profile of CDS when surfactant is not present in the mobile phase that 
disappears in the profiles acquired in the presence of surfactant (Figure 29). This 
indicates that the larger molecular weight species causing the second mode in the profile 
acquired without surfactant is likely several smaller molecular weight chains aggregating 
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together and causing a falsely elevated apparent molecular weight. Aggregation of CDS 
is supported by the addition of surfactant not only resulting in lower MP and MN values, 
but also in the change of shape of the molecular weight distribution profile from bimodal 
to unimodal. 
 
Figure 29. SEC-HPLC chromatogram of CDS showing bimodal distribution of the 
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and 
unimodal distribution of chain lengths when varying concentrations of Tween 80 are used 
in the mobile phase. 
  
CDS contains an aromatic backbone which could logically cause chains to 
aggregate together through energetically beneficial hydrophobic interactions such as π-
π stacking in the absence of surfactant. Addition of surfactant could also logically break 
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up this aggregation and cause the larger molecular weight species to disperse, resulting 
in the unimodal profile of CDS seen when Tween 80 is used in the mobile phase of HPLC. 
The molecular weight distribution profile for heparin can be contrasted with that of 
CDS because the heparin peaks are shifted to the right when surfactant is added whereas 
they move to the left with CDS (Figure 30). This means that the molecular weight of 
heparin is overestimated to a greater degree in the presence of surfactant, whereas the 
molecular weight of CDS was better estimated in the presence of surfactant. Heparin’s 
MP, MN, and MW values are increased when surfactant is present, whereas CDS’s MP and 
MN values are decreased in the presence of surfactant (Table 6). 
Table 6. Peak average molecular weight (MP), Number average molecular weight (MN), 
weight average molecular weight (MW), and polydispersity of CDS and heparin 
CDS MP 
MN 
(~10% error) 
MW 
(~10% error) 
Polydispersity 
No surfactant 9121 ± 170 8604 12242 1.42 
0.01% Tween 80 5582 ± 1219 6567 12606 1.92 
0.02% Tween 80 5742 ± 512 5513 14217 2.58 
0.05% Tween 80 4754 ± 630 5231 9210 1.76 
Heparin MP 
MN 
(~10% error) 
MW 
(~10% error) 
Polydispersity 
No surfactant 18976 ± 726 16410 18267 1.11 
0.01% Tween 80 24988 ± 727 27697 27506 0.99 
0.02% Tween 80 29516 ± 121 26624 30220 1.13 
0.05% Tween 80 21362 ± 984 19795 22616 1.14 
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Figure 30. SEC-HPLC chromatogram of heparin, showing SEC-HPLC conducted with no 
surfactant and varying concentrations of Tween 80 in the mobile phase. 
Although the MP and MN values for CDS appear to follow a trend of indirect 
variation with increasing concentration of Tween 80, this trend is not statistically 
significant. No such trend exists or is also statistically insignificant for the weight average 
molecular weight of CDS or any of the molecular weight averages for heparin.  
Polydispersity is relatively the same for heparin with and without surfactant, where 
as it is increased in the presence of surfactant for CDS. Whatever chains that were 
aggregated when no surfactant was present, are able to disperse and contribute their 
own individual molecular weight to the average when surfactant is present. These 
“additional” free chains could explain why the polydispersity index value is increased 
when surfactant is present.  
The molecular weight distribution breakdown for CDS also changes in the 
presence of surfactant following the same trend as before (Figure 31). The percent of 
59 
 
small chains (less than 6000 Da) nearly doubles when surfactant is added and the percent 
of medium chains (6000-10000 Da) and large chains (greater than 10000 Da) both 
decrease by almost half.  
 
Figure 31. Molecular weight distribution of CDS in the presence and absence of different 
concentrations of surfactant used in the mobile phase for SEC-HPLC analysis 
 
The same molecular weight distribution cut offs are provided for heparin, but 
changes are hard to visualize because the majority of chains in heparin have a molecular 
weight greater than 10000 Da (Figure 32). Because the FDA requires that the ratio of 
chains between 8000-16000 and 16000-24000 in heparin samples be no less than 1.0, a 
breakdown based on those numbers was calculated in addition (Figure 33).26   
60 
 
 
 Figure 32. Molecular weight distribution of heparin in the presence and absence of 
different concentrations of surfactant used in the mobile phase for SEC-HPLC analysis 
 
Figure 33. Larger molecular weight distribution of heparin in the presence and absence 
of different concentrations of surfactant used in the mobile phase for SEC-HPLC analysis 
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 The percent of chains with molecular weight between 16000-24000 Da decreases 
from 69% when no surfactant is present to ~30% in the presence of surfactant (Figure 
33). However, the percent of larger chains (greater than 24000 Da) increases from 12% 
when no surfactant is present to ~30-40% in the presence of surfactant. It is the increase 
in the percent of larger chains that contributes to the overall increase in MP, MN, and MW 
values. The long chains of heparin may be subjected to more physical aggregation in the 
presence of surfactant due to the simple fact that added surfactant adds more molecules 
into the solution and can increase the likelihood of polymer chains to bump in not only to 
one another but also into molecules of the surfactant itself as well. If these long chains 
become entangled with one another or trap surfactant molecules within their aggregate, 
the apparent molecular weight will be falsely elevated, which is what we see in the SEC-
HPLC profiles of heparin (Figure 30). 
Table 7. Attempted mobile phases used in SEC-HPLC and resulting percent 
overestimation of the literature value for molecular weight of CDS and heparin 
 
There is a contrasting behavior of the analogous polymers CDS and heparin in 
solution. Whereas the apparent molecular weight of CDS decreases in the presence of 
surfactant, the apparent molecular weight of heparin increases in the presence of 
surfactant (Table 7). There is no correlation of surfactant concentration with amount of 
molecular weight overestimation; the effect of surfactant on apparent molecular weight is 
concentration independent and similar for all concentrations used (0.01-0.05%). 
Mobile Phase 
Overestimated of literature MW by x Fold 
CDS Heparin 
No Surfactant 2.7 1.3 
0.01% Tween 80 1.7 1.7 
0.02% Tween 80 1.7 2.0 
0.05% Tween 80 1.4 1.4 
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3.4.2.2 Enoxaparin 
 The second control anticoagulant, enoxaparin, behaves much like CDS in that the 
SEC-HPLC profile is shifted to the right in the presence of surfactant (Figure 34). 
Enoxaparin’s apparent molecular weight is overestimated in the absence of surfactant 
and decreases in the presence of surfactant. 
 
Figure 34. SEC-HPLC chromatogram of enoxaparin showing SEC-HPLC conducted with 
no surfactant and varying concentrations of Tween 80 in the mobile phase. 
As with the previous polymers, no trend is observed that depends on the 
concentration of the surfactant and the effect on apparent molecular weight appears to 
be similar for all concentrations of surfactant (Table 8). The polydispersity index of 
enoxaparin was greater when surfactant was used than when it was not (Table 8). 
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Table 8. Peak average molecular weight (MP), Number average molecular weight (MN), 
weight average molecular weight (MW), and polydispersity of enoxaparin 
Enoxaparin MP 
MN 
(~10% error) 
MW 
(~10% error) 
Polydispersity 
No surfactant 7617 ± 302 7737 9549 1.23 
0.01% Tween 80 3000 ± 253 4213 8332 1.99 
0.02% Tween 80 5085 ± 571 6087 9717 1.59 
0.05% Tween 80 3369 ± 331 3967 7072 1.78 
 
The molecular weight distribution breakdown for enoxaparin changes in the 
presence of surfactant following the same trend as CDS did: the increase in percent of 
smaller molecular weight (less than 6000 Da) chains in the presence of surfactant (Figure 
35). Only 8% of chains fall below 6000 Da when surfactant is absent, but this increases 
to 60-80% the percent in the presence of surfactant. The percentage of medium chains 
(6000-10000 Da) decreased from 39% in the absence of surfactant to ~16% in the 
presence of surfactant. The trend was similar for CDS medium chains, which decreased 
by almost half (Figure 31). 
Because the FDA stipulates several requirements for the molecular weight 
distribution pattern of enoxaparin between 2000 – 8000 Da, a breakdown of those 
numbers was calculated in addition (Figure 36). The medium chains (2000 – 8000 Da) 
vary only from 54% to 61%, or roughly half, of the enoxaparin sample tested. 
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Figure 35. Molecular weight distribution of enoxaparin in the presence and absence of 
different concentrations of surfactant used in the mobile phase for SEC-HPLC analysis 
 
Figure 36. Smaller molecular weight distribution of enoxaparin in the presence and 
absence of surfactant used in the mobile phase for SEC-HPLC analysis 
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3.4.2.3 Discussion of CDS and Controls 
Certain stipulations set out by regulatory bodies for control anticoagulants used in 
our studies (heparin and enoxaparin) and the results we achieved are compared in Table 
9. As mentioned in the introduction to heparin, the USP dictates several requirements for 
manufacturers of pharmaceutical grade heparin. The heparin sodium for research we 
used in the SEC-HPLC analysis only met two of these criteria (shown in green) when no 
surfactant was present in the mobile phase (Table 9). 
 Heparin’s apparent molecular weight data was more accurate when compared 
with literature values when measured with no surfactant than when measured with 
surfactant. Enoxaparin was the opposite: apparent molecular weight data was more 
accurate when measured with surfactant than when measured without surfactant. CDS 
also exhibited opposite trends from heparin, similar to enoxaparin. Although CDS was 
originally designed as a mimetic of heparin, its behavior in solution more closely mimics 
that of the LMWH, enoxaparin, rather than that of heparin. 
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Table 9.  Controls heparin and enoxaparin calculated molecular weights from SEC-
HPLC studies comparison with known parameters. Red text indicates the measurement 
fell outside requirements; Green text represents satisfied requirements 
Heparin 
% > 24000 
Da 
Weight average 
molecular 
weight (MW) 
Ratio of chains 
 8000-16000 : 16000-24000 
Required by USP 
< 20% of 
sample 
15000 – 19000 
Da 
≥ 1.0 
Measured with:    
No Surfactant 11.55 18267 0.27 
0.01% Tween 80 33.26  27506 0.82 
0.02% Tween 80 55.53 11488 0.48 
0.05% Tween 80 28.81 22616 0.93 
Enoxaparin Polydispersity 
Peak average 
molecular 
weight (MP) 
% < 
2000 
Da 
% 2000 
-8000 
% > 
8000 
Literature 1.1 – 1.5 4500 <10% 60-72% 22-36% 
Measured with:    
No Surfactant 1.23 7617 41.25 54.03 4.36 
0.01% Tween 80 1.99 3000 30.65 57.92 11.68 
0.02% Tween 80 1.59 5085 14.27 61.1 24.62 
0.05% Tween 80 1.78 3369 33.43 55.69 11.13 
 
3.4.3 Other Sulfated LMWLs (FDS and SDS) 
 Though FDS and SDS SEC-HPLC results are similar to that of CDS, a few 
differences worth noting are mentioned below.  
3.4.3.1 FDS 
 The average SEC-HPLC profile of FDS shifts to the right and changes in shape 
from bimodal to unimodal with the addition of surfactant, similar to how CDS behaved 
(Figure 37). FDS’s apparent molecular weight was 8338 Da when measured without 
surfactant, but dropped ~25% when surfactant was present in the mobile phase (Table 
10). The polydispersity increased ~30% once surfactant was added. 
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Figure 37. SEC-HPLC chromatogram of FDS showing bimodal distribution of the 
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and 
unimodal distribution of chain lengths when varying concentrations of Tween 80 are used 
in the mobile phase. 
 
Table 10. Peak average molecular weight (MP), Number average molecular weight (MN), 
weight average molecular weight (MW), and polydispersity of FDS. *MN and MW for 0.02% 
and 0.05% Tween 80 were calculated solely from FDSBH rather than an average of FDSBH, 
FDSMT, and FDSJT due to sampling error in the excluded samples. 
FDS MP 
MN 
(~10% error) 
MW 
(~10% error) 
Polydispersity 
No surfactant 8338 ± 871 8251 11622 1.41 
0.01% Tween 80 6080 ± 663 8857 15464 1.75 
0.02% Tween 80 7470 ± 828 6586* 17772* 2.37 
0.05% Tween 80 5641 ± 161 6493* 15584* 2.32 
 
 The molecular weight distribution breakdown of FDS without surfactant consisted 
of 41% small chains (< 6000 Da) that increased by ~20% in the presence of surfactant 
(Figure 38). The percentage of medium chains (6000 – 10000 Da) was 31% when 
surfactant was absent and decreased by more than half when surfactant was present. 
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Figure 38. Molecular weight distribution of FDS in the presence and absence of different 
concentrations of surfactant used in the mobile phase for SEC-HPLC analysis 
 
3.4.3.2 SDS 
The average SEC-HPLC profile of SDS also shifts to the right and changes in 
shape from bimodal to unimodal with the addition of surfactant, similar to how CDS and 
FDS behaved (Figure 39). As with the others, the peak average molecular weight 
decreased in the presence of surfactant, but even more drastically by ~60% for SDS 
(Table 11). The number average molecular weight was also decreased in the presence 
of surfactant, but the weight average molecular weight was higher when 0.02% Tween 
80 was present. This anomalous increase and resultant very high polydispersity of more 
than 3 is visible in the profile with a higher baseline than the other data acquired with 
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surfactant (Figure 39). The larger numbers could be explained by the elevated baseline 
which can change for experiments performed on different days as was the case here.  
Figure 39. SEC-HPLC chromatogram of SDS showing bimodal distribution of the 
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and 
unimodal distribution of chain lengths when varying concentrations of Tween 80 are used 
in the mobile phase. 
  
Table 11. Peak average molecular weight (MP), Number average molecular weight (MN), 
weight average molecular weight (MW), and polydispersity of SDS. 
 
SDS has lower molecular weight and shorter chains than CDS and SDS. This is 
expected because sinapic acid, the starting monomer, has an additional methoxy 
functional group in place of a hydrogen that is available on CDS/FDS to react and form 
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the β-5 linkages. Because this hydrogen is not available on SDS, it cannot form β-5 
linkages, and therefore is primarily made up of β-O-4 linkages. Sinapic acid is considered 
to have lower polymerizability than caffeic and ferulic acid. Because of sinapic acid’s 
inability to form β-5 linkages and low polymerizability, the resulting polymer SDS has 
shorter chains and lower molecular weight than CDS and FDS.  
 
The molecular weight distribution breakdown of SDS contained 44% small chains 
(< 6000 Da) when no surfactant was present, but there number of small chains doubled 
when surfactant was present (Figure 40). The percentage of medium chains (6000 – 
10000 Da) was greatly decreased in the presence of surfactant than without surfactant. 
A molecular weight distribution breakdown more representative of the smaller molecular 
weight of SDS was calculated for all mobile phases containing surfactant (Figure 41). 
The apparent molecular weight range of SDS when measured with no surfactant 
was too large to present distribution less than 2000 Da and was not included.  
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Figure 40. Molecular weight distribution of SDS in the presence and absence of different 
concentrations of surfactant used in the mobile phase for SEC-HPLC analysis 
 
Figure 41. Smaller molecular weight distribution pattern more representative of SDS in 
the presence and absence of different concentrations of surfactant used in the mobile 
phase for SEC-HPLC analysis 
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3.4.4 Unsulfated LMWLs: CD, FD, SD 
 Combining SEC-HPLC results of the unsulfated LMWLs with that of their sulfated 
counterparts: CDS, FDS, and SDS gives us insight into the degree of sulfation of the 
sulfated LMWLs. Because each sulfated LMWL was generated from the starting 
unsulfated polymer, the molecular weight of the sulfated LMWL theoretically should be 
increased by the weight of the number of sulfate groups introduced onto the polymer. 
Therefore, subtracting the molecular weight of the unsulfated LMWL from its 
corresponding sulfated LMWL and dividing the resulting difference by the molecular 
weight of a sulfate group, will give us an estimate of the average number of sulfate groups 
present on the polymer. To estimate the number of monomer units per polymer chain, 
one can divide the molecular weight of the unsulfated LMWL by the molecular weight of 
the starting monomer: caffeic, ferulic or sinapic acid. The number of sulfate groups can 
then be divided by the number of monomer units to describe the average degree of 
sulfation of the LMWL. A table of properties for the sulfated LMWLs calculated according 
to the above method is provided in the conclusion of the SEC-HPLC section below. 
3.4.4.1 CD 
 Although slightly less visible for CD, all three unsulfated LMWLs also demonstrated 
the change from bimodal to unimodal profiles due to the addition of surfactant (Figure 42).  
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Figure 42. SEC-HPLC chromatogram of CD showing bimodal distribution of the 
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and 
unimodal distribution of chain lengths when varying concentrations of Tween 80 are used 
in the mobile phase. 
In addition, all unsulfated LMWLs shifted their profiles to the right when surfactant 
was added and had lower peak average molecular weights (Table 12). Also, no trend 
depending on the concentration of surfactant was observed and the effect of surfactant 
on apparent molecular weight can be considered concertation independent. While the MP 
and MN were decreased by about 50% for CD in the presence of surfactant, the MW 
exhibited anomalous results with 0.02% Tween 80 and was increased from 9362 Da 
without surfactant to 10025 Da at this concentration. This could be due to sampling error 
or day to day variation in the baseline of the HPLC system.  
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Table 12. Peak average molecular weight (MP), Number average molecular weight (MN), 
weight average molecular weight (MW), and polydispersity of CD. 
CD MP 
MN 
(~10% error) 
MW 
(~10% error) 
Polydispersity 
No surfactant 7487 ± 311 7376 9362 1.27 
0.01% Tween 80 3025 ± 372 3107 6115 1.97 
0.02% Tween 80 4077 ± 216 4612 10025 2.17 
0.05% Tween 80 3021 ± 96 3145 6605 2.1 
 
 The polydispersity was increased by ~35% when surfactant was added, possibly 
due to larger molecular weight species and aggregates being disrupted by the surfactant 
and contributing additional chains to the overall sample. 
 The molecular weight distribution breakdown of CD revealed that when surfactant 
was added, the proportion of small chains (< 6000 Da) increased from ~60% to ~80% of 
the sample (Figure 43). The percent of medium (6000 – 10000 Da) and large (>10000 
Da) chains decreased about 50% when surfactant was added.  
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Figure 43. Molecular weight distribution of CD in the presence and absence of different 
concentrations of surfactant used in the mobile phase for SEC-HPLC analysis  
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3.4.4.1 FD 
 The SEC-HPLC profiles of FD demonstrate similar trends as discussed for the 
sulfated LMWLs and CD above (Figure 44). 
 
Figure 44. SEC-HPLC chromatogram of FD showing bimodal distribution of the proportion 
of chain lengths when SEC-HPLC is conducted with no surfactant and unimodal 
distribution of chain lengths when varying concentrations of Tween 80 are used in the 
mobile phase. 
 
The weight average molecular weight of FD when measured with 0.02% Tween 
80 also was subject to an anomalous increase over the MW measured with no surfactant, 
as was seen with CD and the other polymers (Table 13). Because this anomaly occurs 
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across several of the data gathered the days when 0.02% Tween 80 was being used, it 
is likely an instrument related discrepancy. The molecular weight distribution breakdown 
of FD was similar to results discussed with CD (Figure 45).  
Table 13. Peak average molecular weight (MP), Number average molecular weight (MN), 
weight average molecular weight (MW), and polydispersity of FD. 
FD MP 
MN 
(~10% error) 
MW 
(~10% error) 
Polydispersity 
No surfactant 6805 ± 558 6547 9756 1.49 
0.01% Tween 80 2620 ± 183 2944 5106 1.73 
0.02% Tween 80 3596 ± 656 4423 13588 3.07 
0.05% Tween 80 2394 ± 50 2667 7430 2.79 
 
Figure 45. Molecular weight distribution of FD in the presence and absence of different 
concentrations of surfactant used in the mobile phase for SEC-HPLC analysis. 
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3.4.4.1 SD 
 The SEC-HPLC profile of SD shows the most obvious bimodal distribution when 
no surfactant is used in the mobile phase of all the LMWLs (Figure 46). Due to the 
presence of only β-O-4 linkages discussed before for SDS, SD may be the LMWL most 
subjected to hydrophobic interactions due to greater availability of the benzene rings in 
the backbone to interact with one another. SD and SDS have enhanced flexibility than 
the other LMWLs due to the absence of the bicyclic β-5 linkage. SD may be even more 
likely to aggregate than SDS due to the absence of large and negatively charged sulfate 
groups in SDS that would electrostatically repel one another. This could all serve to 
explain the enhanced large molecular weight mode seen in the SD profile, which likely 
represents aggregated smaller SD chains.  
Figure 46.SEC-HPLC chromatogram of SD showing bimodal distribution of the proportion 
of chain lengths when SEC-HPLC is conducted with no surfactant and unimodal 
distribution of chain lengths when varying concentrations of Tween 80 are used in the 
mobile phase.   
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An opposite trend was observed with CD and FD, where their sulfated counterparts 
CDS and FDS had higher calculated molecular weights, which could be logically 
explained by the addition of sulfate groups. However, an alternative explanation for the 
increased molecular weight of the sulfated LMWLs could be that the addition of sulfate 
groups actually increases the molecules tendency to aggregate. This is because the 
introduction of dual characteristics (hydrophobic backbone and negatively charged 
functional groups) to the sulfated LMWLs may cause them to associate with themselves 
in a manner similar to cell membranes or micelles, where hydrophobic moieties are 
sequestered together away from water and hydrophilic parts arrange towards water.  
Similar to the other LMWLs, the apparent MP and MN of SD was reduced by ~50% 
when surfactant was used in the mobile phase and polydispersity was increased by ~40% 
(Table 14). Once again the MW measured with 0.02% Tween 80 in the mobile phase was 
anomalous and can be disregarded. 
  
Table 14. Peak average molecular weight (MP), Number average molecular weight (MN), 
weight average molecular weight (MW), and polydispersity of SD. 
SD MP 
MN 
(~10% error) 
MW 
(~10% error) 
Polydispersity 
No surfactant 8849 ± 199 9264 12614 1.36 
0.01% Tween 80 4025 ± 72 4105 6438 1.57 
0.02% Tween 80 5745 ± 245 6975 16331 2.34 
0.05% Tween 80 4060 ± 162 4540 8555 1.88 
 
Similar to the trend seen with the other LMWLs, the molecular weight distribution 
breakdown of SD showed the percent of small chains (< 6000 Da) increase by twice and 
medium (6000-10000 Da) and large (>10000 Da) chains decrease by half (Figure 47). 
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The molecular weight of the unsulfated LMWL, SD, at 8849 Da was higher than 
the molecular weight for sulfated LMWL SDS of 7765 Da. This is unexpected because 
the sulfated LMWL should have a larger average molecular weight than its unsulfated 
precursor due to the weight of added sulfate groups. However, the batch of SD that the 
SDS used in this work was originally synthesized from could have been different than the 
SD sample used in the SEC-HPLC analysis. SDS could also have degraded in solution 
during storage at a greater rate than the SD did, explaining why its molecular weight was 
reduced.   
 
Figure 47. Molecular weight distribution of SD in the presence and absence of different 
concentrations of surfactant used in the mobile phase for SEC-HPLC analysis 
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3.4.5 Batch Variability – CDS and FDS 
 Chromatograms of all individual batches of CDS and FDS are available in 
Appendix 1. 
 Batches of CDS had similar apparent peak average molecular weights when 
measured without surfactant and when measured with 0.02% Tween 80, but batch 
CDSMT1 had a greater MP when measured with 0.01% and 0.05% Tween 80 than the 
other batches (Table 15). A possible explanation for this batch variability could be related 
to stability of the polymer over time because the batches were synthesized several years 
apart. Unfortunately, this explanation won’t work because CDSMT2 was the most recently 
synthesized batch and therefore should have been subjected to less degradation 
reactions over a shorter storage time, and could therefore logically have higher molecular 
weight. Alternative reasons for this batch variability could be related to instrument or 
sampling error or day to day variation in the experiments.  
FDS batches had fairly similar peak average molecular weights for all mobile 
phases except 0.05% Tween 80 (Table 15). The ~30k Da MP calculated for FDSMT and 
FDSJT with 0.05% Tween 80 in the mobile phase is a sampling error of those batches and 
can be disregarded as outliers. 
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Table 15. Peak average molecular weight calculated from SEC-HPLC studies and 
associated error for all mobile phases 
Peak Average Molecular Weight 
Polymer 
Without 
Surfactant 
Tween 0.01 
% 
Tween 0.02 
% 
Tween 0.05 % 
CDSMT1 9251 ± 249 7100 ± 598 5547 ± 334 5641 ± 528 
CDSMT2 9255 ± 19 4729 ± 275 5439 ± 473 4337 ± 192 
CDSBH 9013 ± 177 4916 ± 214 6175 ± 426 4471 ± 117 
FDSMT 8843 ± 392 6377 ± 291 8256 ± 415 30861 ± 1257 
FDSJT 7464 ± 931 6546 ± 911 6713 ± 774 28897 ± 1253 
FDSBH 8936 ± 241 5474 ± 372 6801 ± 360 4804 ± 1453 
  
 Batch variability for CDS’s number average molecular weight was similar to that of 
peak average molecular weight (Table 16). FDSMT and FDSJT were also subjected to 
sampling error when 0.02% and 0.05% Tween 80 was used in the mobile phase, and the 
over 10k Da MN averages should be disregarded. 
 
Table 16. Number average molecular weight calculated from SEC-HPLC studies and 
associated error for all mobile phases 
Number Average Molecular Weight 
Polymer 
Without 
Surfactant 
Tween 0.01 % Tween 0.02 % Tween 0.05 % 
CDSMT1 10343 ± 183 7090 ± 144 5785 ± 354 6112 ± 224 
CDSMT2 10098 ± 76 5792 ± 95 6644 ± 1333 5292 ± 101 
CDSBH 9032 ± 359 5506 ± 72 5808 ± 1107 4889 ± 67 
FDSMT 9327 ± 884 7143 ± 235 16912 ± 1528 19464 ± 110 
FDSJT 9006 ± 1059 6220 ± 61 11707 ± 129 15200 ± 405 
FDSBH 8827 ± 626 6203 ± 97 5808 ± 1107 7641 ± 259 
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Batch CDSMT1 had greater weight average molecular weight than the other two 
batches of CDS across the board regardless of mobile phase (Table 17). FDSMT and 
FDSJT had larger MW than FDSBH across the board regardless of mobile phase. 
Table 17. Weight average molecular weight calculated from SEC-HPLC studies and 
associated error for all mobile phases 
Weight Average Molecular Weight 
Polymer 
Without 
Surfactant 
Tween 0.01 % Tween 0.02 % Tween 0.05 % 
CDSMT1 12203 ± 137 10585 ± 800 16000 ± 43 9116 ± 216 
CDSMT2 11524 ± 91 8566 ± 632 14569 ± 3339 7885 ± 106 
CDSBH 10276 ± 470 8090 ± 431 12335 ± 3149 7138 ± 126 
FDSMT 12462 ± 1512 10994 ± 94 32138 ± 1197 30210 ± 330 
FDSJT 12422 ± 1418 10608 ± 127 27234 ± 202 28154 ± 195 
FDSBH 11354 ± 838 9383 ± 62 12335 ± 3149 14438 ± 937 
 The polydispersity for CDS batches, as well as FDS batches, did not vary 
excessively amongst any of the mobile phases used (Table 18).  
Table 18. Polydispersity index (Mw/Mn) 
Polymer 
Without 
Surfactant 
Tween 0.01 % Tween 0.02 % Tween 0.05 % 
CDSMT1 1.18 1.49 2.77 1.49 
CDSMT2 1.14 1.48 2.19 1.49 
CDSBH 1.14 1.47 2.12 1.46 
FDSMT 1.34 1.54 1.90 1.55 
FDSJT 1.38 1.71 2.33 1.85 
FDSBH 1.29 1.51 2.12 1.89 
 
3.4.6 Alternative Surfactant: Triton X-100 
 Triton X-100 is another non-ionic surfactant used in addition to Tween 80 to see if 
the effect of surfactant on apparent molecular weight was reproducible for multiple 
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surfactants. Tween 80 and Triton X-100 are both polydisperse, heterogeneous mixtures 
themselves and their structures are provided in the Method Development section (Figure 
26). Triton X-100 differs from Tween 80 notably by the presence of an aromatic benzene 
ring its core instead of a tetrahydrofuran core characteristic of Tween 80. Because Triton 
X-100 contains an aromatic moiety, it can engage in hydrophobic interaction with our 
LMWL’s aromatic scaffold. Results for the sulfated LMWLs are below and chromatograms 
for the unsulfated LMWLs and controls heparin/enoxaparin with Triton X-100 in the mobile 
phase are in Appendix 2. 
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Figure 48. SEC-HPLC chromatogram of CDS showing bimodal distribution of the 
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and 
unimodal distribution of chain lengths when varying surfactants are used in the mobile 
phase. 
 The profile for CDS when analyzed with 0.02% Triton X-100 in the mobile phase 
of the HPLC shifts to the left in comparison with the profile when no surfactant is used 
(Figure 48). This is similar to what occurred with the surfactant Tween 80, and the same 
concentration of 0.02% Tween 80 results are included here for direct comparison between 
surfactants. Noticeably, the profile for 0.02% Triton X-100 shows the presence of high 
molecular weight species on the right tail in greater quantity than when the same 
concentration of Tween 80 is used. The Triton X-100 profile even exceeds the second 
mode of high molecular weight species or aggregated chains seen in the profile acquired 
when no surfactant was used. Because the higher molecular weight species are still 
present and present in greater proportion when Triton x-100 is used compared with no 
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surfactant, it is likely that Triton X-100 itself is interacting with CDS through plausible 
hydrophobic interactions. 
Table 19. Peak average molecular weight (MP), Number average molecular weight (MN), 
weight average molecular weight (MW), and polydispersity of CDS, including alternative 
surfactant Triton X-100. 
CDS MP 
MN 
(~10% error) 
MW 
(~10% error) 
Polydispersity 
No surfactant 9121 ± 170 8604 12242 1.42 
0.02% Tween 80 5742 ± 512 5513 14217 2.58 
0.02% Triton X-100 5845 ± 972 7393 11598 1.57 
 
 The apparent peak average molecular weight of CDS decreased by ~35% from 
9121 Da when measured without surfactant to ~5800 Da when either surfactant was 
used in the mobile phase (Table 19).  
 The molecular weight distribution breakdown of Triton X-100 shows a 40% 
increase from 33% of the sample consisting of large chains (> 10000 Da) when no 
surfactant was used in the mobile phase compared with 53% of the sample being large 
chains when Triton X-100 was used (Figure 49). This is in contrast to the trend seen with 
the other surfactant, Tween 80, which had a reduction in the proportion of large chains 
and an increase in the proportion of small chains. Triton X-100 may be effective at 
breaking up aggregation amongst small and medium chains, but may become entangled 
with large chains and aggregate with multiple chains of CDS, evidenced by the 40% 
increase in the proportion of larger molecular weight species.   
87 
 
 
Figure 49. Molecular weight distribution of CDS achieved when SEC-HPLC is conducted 
with no surfactant and the same concentration of two different surfactants in the mobile 
phase. 
 
 The profile of FDS, when analyzed with Triton X-100 in the mobile phase, 
anomalously shifted to the right instead of the left, which was the opposite trend seen 
with the addition of surfactant for all polymers tested aside from heparin (Figure 50). 
Polydispersity is also less at 1.32 when Triton X-100 is used in the mobile phase 
compared to 1.41 when it is not. 
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 Figure 50. SEC-HPLC chromatogram of FDS showing bimodal distribution of the 
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and 
unimodal distribution of chain lengths when varying surfactants are used in the mobile 
phase. Apparent molecular weight is most overestimated in the presence of Triton X-100 
which contains an aromatic group. 
 
 
Table 20. Peak average molecular weight (MP), Number average molecular weight (MN), 
weight average molecular weight (MW), and polydispersity of FDS, including alternative 
surfactant Triton X-100. *MN and MW for 0.02% Tween 80 were calculated solely from 
FDSBH rather than an average of FDSBH, FDSMT, and FDSJT due to sampling error in the 
excluded samples. 
FDS MP 
MN 
(~10% error) 
MW 
(~10% error) 
Polydispersity 
No surfactant 8338 ± 871 8251 11622 1.41 
0.02% Tween 80 7470 ± 828 6586* 17772* 2.37 
0.02% Triton X-100 14200 ± 4806 13923 18442 1.32 
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Two of the three FDS batches were subject to sampling error when 0.02% Tween 
80 was used in the mobile phase, and it is likely that this illogical result is also due to 
sampling error with FDS (Table 20). As an alternative explanation, Triton X-100 could be 
aggregating with FDS through the same hydrophobic interactions possible with CDS 
discussed above. Aggregation of large molecular weight chains of FDS and several 
molecules of Triton X-100 could be characteristic of the increased MP, MN, and MW 
calculated when this surfactant is used compared to when it is not (Table 20). 
 
 
Figure 51. Molecular weight distribution of FDS achieved when SEC-HPLC is conducted 
with no surfactant and the same concentration of two different surfactants in the mobile 
phase. 
 The molecular weight breakdown of FDS when Triton X-100 was used in the 
mobile phase was similar to that of CDS (Figure 51). The percent of small chains (< 6000 
Da) dropped from 41% of the sample when measured with no surfactant to 25% when 
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Triton X-100 was used in the mobile phase. Also, the percent of medium chains (6000 – 
10000 Da) dropped from 31% of the sample when measured with no surfactant to 20% 
when Triton X-100 was used in the mobile phase. However, the percent of large chains 
(> 10000 Da) followed the opposite trend and was increased from 28% when no 
surfactant was used to 52% when Triton X-100 was used in the mobile phase. 
The change in the SEC-HPLC profile of SDS due to the addition of Triton X-100 in 
the mobile phase was once again similar to that of CDS (Figure 52). The MP, MN, and MW 
calculated when Triton X-100 was used in the mobile phase were decreased 30-50% 
compared to when no surfactant was present (Table 21). 
Figure 52. SEC-HPLC chromatogram of SDS showing bimodal distribution of the 
proportion of chain lengths when SEC-HPLC is conducted with no surfactant and 
unimodal distribution of chain lengths when varying surfactants are used in the mobile 
phase. 
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Table 21. Peak average molecular weight (MP), Number average molecular weight (MN), 
weight average molecular weight (MW), and polydispersity of SDS, including alternative 
surfactant Triton X-100 
SDS MP 
MN 
(~10% error) 
MW 
(~10% error) 
Polydispersity 
No surfactant 7765 ± 228 6827 8809 1.29 
0.02% Tween 80 4354 ± 162 3728 12527 3.36 
0.02% Triton X-100 3738 ± 104 4323 6834 1.58 
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Figure 53. Molecular weight distribution of SDS achieved when SEC-HPLC is conducted 
with no surfactant and the same concentration of two different surfactants in the mobile 
phase 
 The molecular weight distribution breakdown of SDS revealed an increase in the 
percentage of small chains (< 6000 Da) from 44% of the sample when no surfactant was 
used to 91% when Triton X-100 was used in the mobile phase (Figure 53). Because of 
SDS’s smaller molecular weight distribution, a breakdown more representative of SDS 
was also calculated (Figure 54). However, the distribution spread from < 1000 to > 2000 
Da was not feasible to calculate for the SDS data acquired with no surfactant, so only the 
two surfactants are compared. While the percent of medium chains (1000 – 2000 Da) is 
similar (~18%) for both surfactants, there were less small (< 1000 Da)  chains (1% vs 
30%) and more large (> 2000 Da) chains (82% vs 55%) when Triton X-100 was used in 
that mobile phase than when 0.02% Tween 80 was used. 
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Figure 54. Smaller molecular weight distribution of SDS achieved when SEC-HPLC is 
conducted with same concentration of two different surfactants in the mobile phase 
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3.5  SEC-HPLC of LMWLs: Conclusions 
SEC-HPLC analysis of LMWLs and control polymers revealed that although 
LMWLs were originally designed as heparin mimetics, in solution they behave more like 
enoxaparin than heparin. The molecular weights of LMWLs and enoxaparin were 
overestimated when no surfactant was used in the mobile phase of the HPLC and 
decreased when surfactant was added. This trend contrasted with heparin, which had 
greater average molecular weight measurements when surfactant was used in the mobile 
phase compared to when surfactant was not present.  
Table 22. Physical properties of sulfated LMWLs and control polymers. Size was obtained 
by dividing the polymer average molecular weight by the weight of monomer unit. Number 
of sulfate groups was obtained by combining sulfated and unsulfated LMWL SEC-HPLC 
results. Peak average molecular weights were calculated from SEC-HPLC studies with 
0.02% Tween 80 in the mobile phase. Because SD had higher molecular weight than 
SDS, data from literature was used when calculations could not be performed. 
 
Range of 
oligomer 
chain length 
Weight 
average 
oligomer size 
Sulfate 
groups per 
monomer 
Peak average 
molecular 
weight (Da) 
CDS 17-47 44 0.4 5742 
FDS 12-50 46 0.5 7470 
SDS 4-1122 14.422 0.3822 4354 
Enoxaparin 6-2722 12.622 1.1422 380022 
Heparin 10-8022 ~4022 1.2822 1300022 
 
The molecular weight of CDS is likely 1.5-2 times higher than the previously reported 
value from elemental analysis of sulfated LMWLs and extrapolated calculations from gel 
permeation chromatography (GPC) HPLC analysis of unsulfated LMWLs (Table 22). The 
higher molecular weight of ~6000 Da is a better estimation of the average size of CDS 
than the previously reported value of 3320 Da because the sulfated LMWLs were directly 
measured on SEC-HPLC.  
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The use of surfactant in the mobile phase of the HPLC likely disrupts LMWLs tendency 
to aggregate due to hydrophobic interactions. Whether 0.01% or 0.05% Tween 80 was 
used, the effect on the apparent molecular weight is relatively similar, therefore the effect 
surfactant is concentration independent. Including Tween 80 in the mobile phase of the 
HPLC at a concentration of as low as 0.01% is likely adequate to disrupt aggregates of 
LMWLs. Even though the surfactant is likely disrupting some high molecular weight 
species, it cannot account for all of the high molecular weight species, indicating the 
presence of some long, heavy chains in the sample. The SEC-HPLC profiles of LMWLs 
change from bimodal when no surfactant is used in the mobile phase to unimodal once 
surfactant is added. The rightmost mode in the bimodal profile likely represents 
aggregated high molecular weight chains. The proportion of high molecular weight chains 
decreases by a factor of 2 in presence of surfactant in the LMWL CDS. 
FDS and SDS behaved with similar trends as CDS, although there are likely a few 
chains in FDS that are longer and bigger than in CDS. SDS has average molecular weight 
values less than that of CDS and FDS. This is expected because sinapic acid, the starting 
monomer of the SDS polymer, can’t form B-5 linkages due to substitutions with more 
methoxy groups than the other cinnamic acid derivatives, caffeic and ferulic acid. Sinapic 
acid does not have an available hydrogen to generate the appropriate radical for β-5 
linkage formation, and therefore exhibits less polymerizability than caffeic and ferulic acid. 
SDS is less polydisperse than CDS and FDS, as expected due to the lower degree of 
polymerizability and more uniform, primarily β-O-4 linkage pattern.  
The use of an alternative surfactant, Triton X-100, in the mobile phase of the HPLC 
resulted in anomalous molecular weight distribution profiles. Triton X-100 contains an 
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aromatic ring that could possibly engage in π-π stacking and other hydrophobic 
interactions with aromatic scaffold of LMWLs. The possible hydrophobic interactions with 
this surfactant in the mobile phase of the HPLC could explain the anomalous trend in 
molecular weight distribution profiles of the LMWLs. 
3.6 Molecular Dynamics Simulations 
Theoretical methods are becoming more sophisticated and computational 
chemistry is being seen as an increasingly useful tool to medicinal chemists.67 Molecular 
dynamics (MD) is the science of simulating the motions of a system of particles and gives 
the fluctuations in relative positions of atoms as a function of time.68 Small, rigid molecules 
may have only one conformation that contributes to the properties of a system, whereas 
larger more flexible molecules (like polymers) have several conformations.67 All atoms in 
the molecular system have a vector direction, velocity, and mass; and force is exerted by 
the atoms on one another.69   
MD simulations give a trajectory of molecule conformations over time of a system 
by integrating Newton’s equations of motion.69 Computational molecular dynamics (MD) 
simulations may be well suited to the study of polymers because they allow for sampling 
of the conformational space that polymers can occupy. Polymers are not rigid entities, 
rather they are highly flexible and can adopt a number of conformations in solution and 
interact not only with themselves and other polymer chains, but with the solvent molecules 
surrounding them as well. The conformational diversity of polymers has a significant 
impact on their physicochemical and biological properties, so modeling the behavior of 
LMWLs with MD simulations can give important insight to understanding their nature in 
solution.70 
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Details of molecular structures and interactions can be predicted by using quantum 
mechanics, but computational costs can be extremely high even for small molecules – 
polymers are even more difficult.71 MD simulations are advantageous because of their 
relatively low cost, but appropriate force fields and parameters are needed to conduct 
them. Force fields consist of equations chosen to model potential energy, but there is no 
unique solution for the optimal set of functions and parameters.71 The goal of a force field 
is to provide good quality geometries and relative energies for a myriad of organic 
molecules through energy minimization.72 Descriptions of atoms, bonds, and angles are 
parameters that need to be available in the force field that is an appropriate model of a 
system.73  
It would be difficult and computationally expensive to define parameters to be an 
appropriate model of CDS using the force fields CHARMM or Amber due to the amount 
of quantum mechanics calculations needed for polymers. CHARMM and Amber were 
developed in response to the need for modeling in specific areas and can accurately 
describe narrow classes of compounds.72 However, a major assumption in attempting to 
model CDS is that any one structure is an accurate representation of the polydisperse, 
heterogeneous mixture that CDS exists as in reality.  
Because CDS molecules are not structurally defined, it is hard to define suitable 
parameters to model CDS accurately. The Tripos force field was chosen for MD 
simulations of CDS because it has been shown to produce molecular geometries close 
to the crystal structure of a diverse selection of molecules.72 Although the Tripos force 
field might not be ideal, we chose to use Tripos because it has been successful previously 
to describe a large variety of molecules and is highly generalizable.72 
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In molecular dynamics simulations, only a small fraction of the total conformational 
space accessible to the polymer is sampled in a time period of 10 – 100 picoseconds.69 
The limited sampling of the conformational space available for a molecular system is a 
major source of error in simulations of macromolecules.69 
3.6.1 Introduction: SEC-HPLC Background 
The sulfated dehydropolymer of caffeic acid (CDS) is a synthetic polymer designed 
as a mimetic of the well-known anticoagulant unfractionated heparin (UFH). CDS has 
shown good activity as an anticoagulant and anti-emphysema agent.5-9 Although 
developed as a heparin mimetic, it has a dramatically different scaffold than UFH. Where 
CDS contains an aromatic, hydrophobic backbone, heparin has a polysaccharide 
backbone. To investigate whether different backbones induce different physicochemical 
properties, we performed size exclusion chromatography (SEC) of CDS and UFH in the 
presence and absence of non-ionic surfactants. While the molecular weight of CDS was 
determined to be closer to the reported literature value in the presence of surfactant, 
UFH’s molecular weight was over estimated.  
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Figure 55. Conflicting trend in behavior of apparent molecular weight from SEC-HPLC 
studies between A) CDS and B) Heparin with and without the presence of Tween 80 in 
the mobile phase 
 
Figure 56. A comparison of heparin and CDS showing opposite trends of molecular 
weight in the presence and absence of surfactant 
 
The peak average molecular weight of CDS was determined from SEC-HPLC 
studies to be overestimated from the reported literature value of 3320 Da by 2.74 times 
when no surfactant was present, but only 1.65 times on average in the presence of 
surfactants (Figure 55). The peak average molecular weight of heparin followed an 
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opposite trend in that it was overestimated from the literature value of 13000 Da by 1.56 
times in the absence of surfactant, but by 2.23 times in the presence of 0.02% Tween 80 
(Figure 56). We hypothesized that the hydrophobicity of CDS was likely to induce 
aggregation in aqueous solution in the absence of a surfactant (Figure 57). In contrast, 
the hydrophilicity of heparin was likely to induce aggregation in the presence of a 
surfactant. To support this hypothesis, molecular dynamics (MD) simulations were 
performed using explicit solvation in Sybyl to model the polymers with and without 
surfactant.  
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Figure 57. Concept of aggregation and rational for addition of surfactant to mobile phase 
of SEC-HPLC 
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3.6.2 Methods 
 The polymers heparin and CDS were modeled with approximate structures using 
the pentasaccharide sequence to represent heparin and a 7-monomer unit long chain of 
CDS with 2 sulfate groups (Figure 58). Tween 80 was modeled with even length chains, 
even though in reality Tween 80 itself is also a heterogeneous mixture. The assumption 
that the selected structures used in modeling are representative of all the possible 
structures in the sample is a major limitation, as far greater size chains may behave 
entirely different than the one structure used.  
 After molecule files were created for heparin, CDS, and Tween 80 alone, heparin 
and Tween 80 were merged together as well as CDS and Tween 80 for a total of five 
separate files. Molecules were energy minimized and then solvated before being energy 
minimized again. Charged sulfate groups were balanced with positively charged sodium 
counter ions (8 in heparin and 2 in CDS) in all simulations to ensure the overall charge of 
the system was zero. 
The simulation was run with Boltzmann initial velocities at 300 K using the Tripos 
force field and Gasteiger-Huckel charges with periodic boundary conditions applied and 
a dielectric function of distance. Sybyl outputs energy of the system after MD runs are 
completed and the changes in interaction energies (ΔG) can be compared for heparin 
and CDS with and without surfactant. Because aggregation is a favored energetic state 
due to the contribution of increased entropy of the system overall due to displacement of 
water molecules upon aggregation, it would be expected that an aggregate would have a 
lower energy calculation than non-aggregated species. A surfactant that serves to break 
up aggregation of polymer chains would have favorable (lower energy) interactions with 
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the polymer. We therefore hypothesize that the change in interaction energy for CDS and 
Tween 80 will be more favorable than the change in interaction energy for heparin and 
Tween 80. 
 
Figure 58. The structures of heparin, CDS, and Tween 80 used in MD simulations 
selected as the best representation the polydisperse, heterogeneous mixtures 
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MD simulations were performed using explicit solvation in Sybyl to model the 
polymers with and without surfactant. Before the production run, two equilibration runs 
were completed to ensure the system was at equilibrium. The first equilibration run was 
an isothermal-isobaric run where the amount of substance (N), pressure (P), and 
temperature (T) are conserved (NPT). The second equilibration run required the amount 
of substance, volume (V), and temperature to be held constant (NVT). Each equilibration 
was run with Boltzmann initial velocities at 300 K using the Tripos force field and 
Gasteiger-Huckel charges with periodic boundary conditions applied and a dielectric 
function of distance for 1000 iterations. Once the volume and pressure had reached 
equilibrium, the final production NVT run could begin with the same parameters but run 
for 100,000 iterations. The changes in interaction energies (ΔG) were calculated and 
compared for heparin and CDS with and without surfactant from the following equation: 
ΔGinteraction = ΔG(polymer + Tween 80) – (ΔGpolymer + ΔGTween 80) 
3.6.3 First set of MD simulations - Results 
For the first round of MD simulations, solvation was achieved by surrounding 
molecules with 20 shells of water using explicit solvation in Sybyl and molecular 
silverware. This resulted in water boxes around each molecule or molecule pair of 
different sizes (Figure 59).  Because we are comparing the energies calculated from the 
entire system, the differing number of water molecules in each system are contributing a 
varying energy to the system. To account for the effect of differing number of water 
molecules in each box, an attempt to normalize the resulting data for comparison was 
necessary by dividing calculated energy values by the number of heavy atoms in each 
105 
 
box. A modified equation reflecting the energy values per heavy atoms was then utilized 
to calculate the interaction energy: 
 
 
 
 
 
 
 
 
Figure 59. Sizes of water boxes used in first set of MD simulations
 
 The equilibration runs were successful in ensuring that the system was at 
equilibrium and the pressure and temperature had stabilized. Example graphs of pressure 
and temperature for the CDS water box at equilibrium are provided (Figure 60). 
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The average potiential, kinetic, and total energy for a all five systems once they 
had reached equilibrium for the first set of  MD production runs is reported below (Table 
23). 
Figure 60. Results after equilibration runs for CDS in a water box 
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Table 23. Results from the first set of MD simulations 
 
 Because of the differing number of water molecules in each box, adjusted 
calculations are also provided (Table 24). 
Table 24. Per weight of heavy atom energies calculated from the first set of MD 
simulations 
 
The ΔGinteraction per heavy atom for CDS and Tween 80 was -0.0711 kcal/mol/ 
heavy atom, lower (more negative = more favorable) than the ΔGinteraction per heavy 
atom for heparin and Tween 80 of -0.0691 kcal/mol/ heavy atom. Although these values 
  
A
v
e
ra
g
e
 P
o
te
n
ti
a
l 
E
n
e
rg
y
 (
k
c
a
l/
m
o
l)
 
S
t.
 D
e
v.
 
A
v
e
ra
g
e
 K
in
e
ti
c
 
E
n
e
rg
y
(k
c
a
l/
m
o
l)
 
S
t.
 D
e
v.
 
A
v
e
ra
g
e
 T
o
ta
l 
E
n
e
rg
y
(k
c
a
l/
m
o
l)
 
S
t.
 D
e
v.
 
A
v
e
ra
g
e
 T
e
m
p
. 
(K
) 
S
t.
 D
e
v.
 
A
v
e
ra
g
e
 P
re
s
s
u
re
 (
a
tm
) 
S
t.
 D
e
v.
 
“C
o
n
s
ta
n
t”
 V
o
lu
m
e
 (
Å
3
) 
C
o
n
s
ta
n
t 
D
e
n
s
it
y
 (
g
/m
L
) 
HEPARIN -8917 69 15034 76 6117 9 292 1 27915 198 128500 1.35 
CDS -10646 63 18692 67 8046 11 290 1 27007 100 161752 1.34 
TWEEN -16870 86 30471 73 13601 19 291 1 28728 114 260182 1.35 
CDS 
+ TWEEN 
-17687 65 31481 59 13794 18 292 1 27581 107 270214 1.34 
HEPARIN 
 + 
TWEEN 
-23343 89 40683 78 17339 14 292 1 27210 67 348943  1.34 
 Average Total Energy 
(kcal/mol) 
Average Energy Per Weight of 
Heavy Atoms 
Heparin 6117 0.0658 
CDS 8046 0.0700 
Tween 13601 0.0724 
CDS + Tween 13794 0.0712 
Heparin + Tween 17339 0.0691 
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may be close enough to one another to call into question the statistical significance of 
the difference, they are weighed per heavy atom. This result is in line with what we 
expected from our hypothesis that Tween 80 and CDS interact more favorably than 
Tween 80 and heparin. 
3.6.4 Second set of uniform box size MD simulations 
 To eliminate the additional step of calculating the energy per heavy atom and to 
minimize the associated potential for increased error, a second set of MD simulations was 
performed in water boxes of the same size. The largest water box from the first set of 
simulations contained heparin and Tween 80 along with 15,508 molecules of water and 
was ~80 Å in diameter. Therefore, a water box of ~80 Å in diameter was created through 
explicit solvation in Sybyl using molecular silverware. The number of heavy atoms in 
heparin, CDS, and Tween 80 was used to delete the same number of water molecules 
from each box before merging the molecule or molecule pair into the box in effort to keep 
the density of all boxes the same. Boxes were then energy minimized and equilibrated as 
was done in the first set of simulations. The same method and dynamics parameters were 
used for the second set of MD simulations as discussed above. 
The second set of MD simulations revealed that the interaction energy of CDS 
and Tween 80 (ΔG = -28,887 ± -664 cal/mol) was slightly more favorable than that of 
heparin and the surfactant (ΔG = -28,070 ± -952 cal/mol), but the difference was not 
statistically significant (Table 25). However, the results may still support our hypothesis 
and showed the same trend seen for the first set of MD simulations. 
ΔG
Tween
 
Wt. of Heavy 
Atoms 
ΔG
Tween
 
Wt. of Heavy 
Atoms 
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Table 25. Results from the second set of MD simulations 
 
 A third set of MD simulations was planned by introducing a second molecule of 
each polymer to better model aggregation between two chains of polymer rather than the 
interaction of the surfactant with one molecule of polymer. Four boxes of the same size 
that consisted of two molecules of heparin, two molecules of heparin with Tween 80, two 
molecules of CDS, and two molecules of CDS with Tween 80 were created. From MD 
simulations, we could calculate the interaction energies of two polymer chains with each 
other, as a model of a polymer aggregate, and compare it with the change interaction 
energy of that aggregate model when Tween 80 is present. Unfortunately, the size of the 
water box necessary to fully solvate the system when three molecules are present (2 
molecules of polymer and 1 molecule of Tween 80) was too large for Sybyl to run 
dynamics simulations and violated the periodic boundary conditions.3.7 MD 
Simulations: Conclusions  
Preliminary results showed that the interaction energy of CDS and the surfactant, 
Tween 80, was more favorable than that of UFH and Tween 80. A subsequent improved 
experiment with water boxes of the same size confirmed this result and supported our 
hypothesis. Aggregation is a favorable interaction (lower energy) due to the contribution 
108 
 
of increased entropy of the system overall due to displacement of water molecules upon 
formation of the aggregate. A surfactant that serves to break up aggregation of polymer 
chains should have favorable (lower energy) interactions with the polymer. While both 
CDS and heparin had favorable interactions with Tween 80, represented by the negative 
change in interaction energies calculated from MD simulations, CDS had slightly more 
negative, therefore more favored interactions with Tween 80.  
Although developed as a heparin mimetic, it has a dramatically different scaffold 
than heparin. Where CDS contains an aromatic, hydrophobic backbone, heparin has a 
polysaccharide backbone. While the molecular weight of CDS was determined from SEC-
HPLC studies to be closer to the reported literature value in the presence of surfactant, 
heparin’s molecular weight was over estimated. This supports our hypothesis that the 
hydrophobicity of CDS likely induces chemical aggregation in aqueous solution in the 
absence of a surfactant. In contrast, the hydrophilicity of heparin likely induces physical 
aggregation in the presence of a surfactant. The combination of MD results with those 
from SEC-HPLC suggest that although CDS functions as a biological mimetic of heparin, 
it is not a chemical mimetic and behaves differently in solution due to the two diverse 
scaffolds. 
MD is a possible way to model polymers behavior in solution, but theoretical 
models require some assumptions and are subject to several limitations. Our first 
assumption is that the structures we used in MD simulations are adequate 
representations of the polydisperse, heterogeneous polymer mixtures. This is a major 
assumption, because LMWLs and heparin do not have a completely defined structure 
and how the polymer really exists in solution is unknown. Other limitations of this work 
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include whether sampling was adequate over the time of the MD run, which is also 
unknown.  MD was a useful tool to learn more about polymers behavior in solution and 
help explain the contrasting trend of molecular weight estimation in the presence and 
absence of surfactants seen from SEC-HPLC studies. Many challenges exist with the 
development of appropriate parameters to describe sulfated compounds and future work 
to establish the validity of modeling polymer aggregation is needed.  
4. Physicochemical Characterization of LMWLs 
4.1 Introduction 
While the previous chapter discussed efforts to characterize the structure of 
sulfated LMWLs, the following chapter is a summation of measured physicochemical 
properties of the same LMWLs used in SEC-HPLC studies. Characterization of 
physicochemical properties, in addition to structural characterization, is another important 
part of the information that has to be established in developing polymers as drugs. In an 
attempt to estimate the hydrophobicity of sulfated LMWLs, we measured the octanol-
water distribution coefficient of the library. Elemental analysis results provided us with the 
amount of carbon, hydrogen, and sulfur content of two batches of the sulfated LMWL 
CDS. Studies of various linkage patterns, degrees of sulfation, and extent of 
decarboxylation revealed structures of CDS that matched closely with the elemental 
analysis results and are the best representation of the structure of CDS described to date.  
4.2 Octanol-water distribution coefficient (log D) 
The octanol-water distribution coefficient (log D) is a measurement of a molecules 
concentration ratio between two immiscible solvents at equilibrium. Log D can give an 
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estimate of a molecules hydrophobicity/hydrophilicity and aid in our prediction of its 
tendency dispersed in aqueous or organic solution as well as its likelihood to penetrate 
lipophilic cell membranes. A drug’s ability to cross cell membranes is usually thought to 
be limited when molecular weight surpasses 500 Da, but the sulfated LMWLs synthesized 
in our lab have shown ability to get into cells and have a predicted molecular weight above 
3000 Da. The aromatic nature of the backbone of sulfated LMWLs may be imparting an 
overall hydrophobic character to the polymers, allowing them to snake through cell 
membranes despite their large size and negative sulfate and carboxylic acid functional 
groups.  
To further characterize the physicochemical properties of LMWLs, log D was 
measured for a handful of related control molecules, the unsulfated polymers (CD, FD, 
SD) and the sulfated polymers (CDS, FDS, SDS). Control compounds chosen include the 
monomer of each polymer in our LMWL library: caffeic acid (CA), ferulic acid (FA), and 
sinapic acid (SA). Also chosen were acetylsalicyclic acid (ASA), salicylaldehyde (S), and 
p-toluic acid (PT) due to their benzene core and carboxylic acid or hydroxyl functional 
groups that are also present in LMWLs. Finally, p-toulenesulfonic acid (PTS) and 5-
sulfosalicylic acid (5SS) were also used as controls due to their benzene core and sulfate 
functional groups, which are important modifications on the sulfated LMWLs. Chemical 
structures and relevant literature values related to estimates of hydrophobicity are 
provided for the controls (Table 26).
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Table 26. Literature search results for various physicochemical properties of control compounds tested on our Log D 
measurement system. (Abbreviations) for control compounds used in results figures. 
Name Structure Log Kow Estimated Log P tPSA 
Molar Absorption 
Coefficient (ɛ) 
(L mol-1 cm-1) 
Caffeic Acid 
(CA) 
 
1.35 ± 0.0474 
1.15±0.4775 
1.58±0.4976 
1.18±0.4777 
77.76 
81.0074 
1480078 
 
Ferulic Acid 
(FA) 
 
 
1.42±0.4775 
1.62±0.4976 
1.70±0.4877 
66.76 1660079 
Sinapic Acid 
(SA) 
 
 
1.29±0.4775 
1.36±0.4976 
1.83±0.5677 
75.99 1780080 
Acetylsalicylic Acid 
(ASA) 
 
-1.2 (pH 7.4, 
phosphate buffer)81 
1.18±0.4775 
1.24±0.4976 
0.96±0.4877 
63.6 110082 
Salicylaldehyde 
(S) 
 
1.65 (pH 5.6, 
phosphate buffer)83 
1.20±0.4775 
1.46±0.4976 
0.83±0.3177 
57.53 
12000 
(255nm)84 
p-toluic Acid 
(PT) 
 
2.3685 
2.08±0.4775 
2.21±0.4976 
1.64±0.2877 
37.3 
12598 
(252nm)86 
p-toluenesulfonic 
Acid 
(PTS)  
 
1.68±0.4775 
1.90±0.4976 
0.96±1.4377 
54.37 
351 
(262nm)87 
5-sulfosalicylic Acid 
(5SS) 
 
 
0.36±0.4775 
0.85±0.4976 
-0.49±1.6777 
111.9 
31600 
(292nm)88 
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4.2.1 Log D Measurement Methods 
Molar absorption coefficients (ɛ) were established for our system by analyzing four 
known concentrations (1, 5, 10, and 20uM) of control compounds at their λmax and 
establishing calibration curves (Figure 61). Similarly, the molar absorption coefficients for 
our library of polymers was measured on our system and used in calculations to 
determine log D (Figure 62).  
 Log D measurements were taken at room temperature from 1.5mL screw-cap 
glass vials that contained 500uL aqueous buffer (20mM sodium phosphate pH 7.4) and 
500uL 1-octanol. Each compound was added by taking 10uL of 5mM stock solutions and 
pipetting into the interface of the solvents. Vials were shaken vigorously for 2 minutes and 
left on inversion table overnight. Vials were allowed to equilibrate for 72 hours on the 
bench without shaking to minimize the effect of micro-droplets of octanol being dispersed 
in the aqueous buffer. Preliminary experiments conducted over six days revealed that log 
D measurements did not change significantly after 24 hours of equilibration time, 
providing support for our use of 72 hours being more than adequate to achieve full 
equilibration. After equilibration was ensured, 5uL samples of the aqueous buffer layer 
were withdrawn and diluted to 100uL for analysis on the UV-spectrometer and 
absorbance was recorded for each compounds’ λmax. Concentration in the 1cm cuvette 
was calculated using the molar absorption coefficient measured on our system for each 
compound and the Beer-Lambert law: 
A = ɛ b [C] 
where A is absorbance, ɛ is the molar absorption coefficient, b is the path length through 
the cuvette, and [C] is the concentration. The concentration in the log D measurement 
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vial was then back-calculated from the cuvette concentration and the ratio of 
concentration between octanol:water (log D) was determined using the known 
concentration of compound originally added to the vial.  
4.2.2 Results and Discussion 
 Results for the molar absorption coefficients of control compounds were compared 
with values found in the literature, although information on the methods of measurement 
of literature values were not always included with the source. Molar absorption 
coefficients may differ based on the buffer in which they are dissolved or the wavelength 
at which they are measured, so direct comparison of our values with literature values may 
not be generalizable. However, the control compounds CA, FA, SA, S, and PTS had 
relatively similar measured molar absorption coefficients to the literature values, whereas 
ASA, 5SS, and PT did not agree well (Figure 63).63-65,67,69-71,73 
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y = 0.0105x + 0.0021
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Figure 61. Known concentrations of control molecules analyzed on our system to 
calculate molar absorption coefficients needed for log D calculations 
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Figure 63. Comparison of molar absorption coefficients found in the literature 
and measured on our system for control compounds 
Figure 62. Known concentrations of library molecules analyzed on our system to 
calculate molar absorption coefficients needed for log P calculations 
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Molar absorption coefficients for library compounds were also measured. Heparin 
and enoxaparin were included in the analysis, but defied the Beer-Lambert principle of 
concentration being directly proportional to absorbance and were not tested in log D 
experiments (Figure 62).  
 Preliminary experiments were conducted over an extended period to determine 
how long compounds took to equilibrate between organic and aqueous phases in the log 
D measurement vial. The log D measurements after 24 hours were averaged together 
and did not have large standard deviation from the average for the control compounds 
tested, with the exception of p-toluenesulfonic acid which had large error in 
measurements regardless of time of measurement (Figure 64). 
 
Figure 64. Log D measurements of control compounds conducted over six days and 
averaged measurements after 24 hours 
 
D
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Average measured log D values of the control compounds from three subsequent 
separate experiments were compared with literature values as well as with calculated log 
P (C log P) values determined by predictive computer software (Figure 65). Compounds 
CA, SA, ASA, and S were found to be in good agreement with literature values, whereas 
FA, 5SS, PT, and PTS were not in such good agreement. Based on the disagreement of 
both sulfated control compounds with literature values, our log D measurement method 
may not be valid for similar compounds. However, because monomers and polymers are 
known to behave differently and because of the good agreement of half the control 
compounds and two of the monomers of LMWLs with literature log D values, we continued 
with the method for testing the library compounds. 
 
Figure 65. Control molecules average measured log D from three trials compared with 
Log P literature values 
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Table 27. Measured molar absorption coefficients and Log D values for control 
compounds 
 
Molar absorption coefficient values and measured average log D values of control 
compounds are summarized in Table 27. 
Name Structure 
Molar Absorption 
Coefficient (ɛ) 
(M-1cm-1) 
Log D 
Caffeic Acid 
 
12138±2701 
(282nm) 
0.916±0.089 
Ferulic Acid 
 
11113±1982 
(282nm) 
0.761±0.065 
Sinapic Acid 
 
10600±663 
(282nm) 
0.793±0.148 
Acetylsalicylic Acid 
 
7600±2285 
(220nm) 
0.494±0.019 
Salicylaldehyde 
 
7438±492 
(256nm) 
1.265±0.134 
5-sulfosalicylic Acid 
 
9463±423 
(236nm) 
0.929±0.089 
p-toluenesulfonic 
Acid 
 
10338±1109 
(236nm) 
0.757±0.168 
p-toluic Acid 
 
8650±238 
(222nm) 
0.753±0.036 
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Molar absorption coefficient values and measured average log D values of library 
compounds are presented below (Table 28) (Figure 66). Three batches each of FDS and 
CDS were compared and found to show minimal batch variability in measured average 
molar absorption coefficient: 71301 ± 12480 L mol-1 cm-1 (CDS); 95629 ± 15457 L mol-1 
cm-1 (FDS) and log D: 0.96 ± 0.09 (CDS) and 0.96  ± 0.06 (FDS).  
Table 28. Measured molar absorption coefficients and log D values of library compounds, 
including three batches each of CDS and FDS averaged from three trials. 
Name 
Molar Absorption Coefficient (ɛ) 
L mol-1 cm-1 
Log D 
CDSMT1 74283 ± 10786 1.06 ± 0.11 
CDSMT2 57600 ± 10958 0.87 ± 0.09 
CDSBH 82021 ± 7341 0.96 ± 0.09 
FDSMT 102650 ± 22495 0.93 ± 0.09 
FDSJT 77908 ± 14600 1.04 ± 0.1 
FDSBH 106329 ± 19024 0.93 ± 0.09 
SDS 107396 ± 60358 1.11 ± 0.11 
CD 74563 ± 3018 0.8 ± 0.08 
FD 110288 ± 6417 1.06 ± 0.11 
SD 45329 ± 7699 0.88 ± 0.09 
 
Figure 66. Average measured log D values of LMWL library, showing sulfated (darker 
shade) and unsulfated polymers (lighter shade) grouped by colors 
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  Average Log D values for sulfated and unsulfated LMWL are compared in Figure 
66. In the case of CDS and SDS, the corresponding unsulfated LMWL (CD and SD) had 
lower log D values compared with their sulfated counterpart. This is an interesting result 
because one would expect a sulfated polymer with additional negative charges to be more 
hydrophilic than its unsulfated precursor. This result indicates the importance of 
recognizing that functional groups and overall charge are not necessarily the largest 
contributor to the molecules overall character and behavior in solution. In the case of 
FDS, the unsulfated precursor FD had a higher log D than FDS, which was the opposite 
trend seen in the other two LMWLs. This could possibly be accounted for by the 
observation early on from the control compounds where the FDS precursor, FA, had a 
measured log D value on our system that was not in good agreement with the literature 
value, whereas there was better agreement for both other LMWL precursors CA and SA. 
 4.2.3 Conclusions 
For LMWLs that contain a number of negatively charged functional groups, it may 
appear at first that these molecules would be very hydrophilic. However, results from log 
D measurement indicate the library of LMWLs have log D around 1. Molecules with log D 
values of close to 1 are approximately 10 times more concentrated in the organic phase 
than the aqueous phase. Although the molecules contain charges, their aromatic 
backbone imparts overall hydrophobic character to the molecules.  
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4.3 Elemental Analysis 
4.3.1 Introduction 
Elemental analysis is a destructive process that reveals the elemental makeup of 
a sample. We sent samples of two batches of CDS (CDSMT1 and CDSMT2) to Atlantic 
Microlab, Inc. to be analyzed for carbon, hydrogen, nitrogen, and sulfur content (although 
nitrogen is not expected to be present in our LMWLs). They did not offer oxygen amount 
evaluation. 
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4.3.2 Results 
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Table 29. Elemental analysis results for two batches of CDS and the average of both 
batches 
 CDSMT1 CDSMT2 Average 
 % content Error % content Error % content Error 
Carbon 47.54 0.04 40.54 0.13 44.04 4.04 
Hydrogen 3.60 0.06 3.57 0.01 3.58 0.04 
Nitrogen 0.57 0.01 0.55 0.01 0.56 0.01 
Sulfur 1.76 0.06 3.74 0.04 2.75 1.14 
 
4.3.3 Discussion 
The two batches of CDS had relatively similar elemental composition, with less 
sulfur content in batch CDSMT1 which was synthesized in 2010 compared with CDSMT2 
synthesized in 2015, possibly due to the greater amount of time to undergo desulfation 
(Table 29). Carbon and hydrogen content were similar to previously published elemental 
analysis data for CDS, but sulfur content was much less than expected (5.3% in literature 
vs 2.75% on average for CDSMT1 and CDSMT2). 
In attempt to determine what the elemental composition results may look like 
structurally, an investigation of varying linkage patterns, degrees of sulfation, and extent 
of decarboxylation was undertaken for polymers of 10-monomer units in length.   It was 
found that for CDSMT1, a polymer containing six β-O-4 linkages, three β-5 linkages, one 
sulfate group, and no decarboxylation was the best match with elemental analysis results.  
Water is likely bound electrostatically to CDS, and we found that inclusion of six water 
molecules in the structure resulted in the best matching elemental percentages. For 
CDSMT2, the best matching structure was made up of six β-O-4 linkages, three β-5 
linkages, three sulfate groups, no decarboxylation, and fourteen added water molecules 
(Table 30).  As further support of these structures being the best representation of the 
structure of CDS, computer calculated elemental composition and molecular weight of 
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CDS polymers 5, 7, 8, 10, and 13 monomer units in length containing 100% β-O-4 
linkages (Table 31) and 100% β-5 linkages (Table 32) are provided for comparison.
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Table 30. Closest matching polymer structures for two batches of CDS 
Monomer 
Units 
Chemical Info Structure 
10 
CDSMT1 
Chemical 
Formula: 
C90H77Na12O56S 
 
Molecular 
Weight: 
2362.49 
 
Elemental 
Analysis:  
C, 45.76 
H, 3.29 
Na, 11.68 
O, 37.92 
S, 1.36 
 
10 
CDSMT2 
Chemical 
Formula: 
C90H91Na13O70S3 
 
Molecular 
Weight: 
2687.70 
 
Elemental 
Analysis:  
C, 40.22 
H, 3.41 
Na, 11.12 
O, 41.67 
S, 3.58 
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Table 31. Structures and elemental analysis for CDS chains of 5, 7, 8, 10, and 13 uniformly Beta-O-4 linked monomer units 
in length 
Mono
-mer 
Units 
Chemical Info Structure 
5 
Chemical 
Formula: 
C45H35Na7O28S 
Molecular 
Weight: 
1216.74 
Elemental 
Analysis:  
C, 44.42 
H, 2.90 
Na, 13.23 
O, 36.82 
S, 2.63 
 
7 
Chemical 
Formula: 
C63H50Na8O38S 
Molecular 
Weight: 
1631.03 
Elemental 
Analysis:  
C, 46.39 
H, 3.09 
Na, 11.28 
O, 37.27 
S, 1.97 
 
126 
 
8 
Chemical 
Formula: 
C72H57Na9O43S 
 
Molecular 
Weight: 
1849.17 
 
Elemental 
Analysis: 
C, 46.77 
H, 3.11 
Na, 11.19 
O, 37.20 
S, 1.73 
 
10 
Chemical 
Formula: 
C90H71Na11O53
S 
 
Molecular 
Weight: 
2285.45 
 
Elemental 
Analysis:  
C, 47.30 
H, 3.13 
Na, 11.07 
O, 37.10 
S, 1.40 
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13 
Chemical 
Formula: 
C117H91Na15 
O71S2 
 
Molecular 
Weight: 
3041.91 
 
Elemental 
Analysis:  
C, 46.20 
H, 3.02 
Na, 11.34 
O, 37.34 
S, 2.11  
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Table 32. Structures and elemental analysis for CDS chains of 5, 7, 8, 10, and 13 uniformly Beta-5 linked monomer units in 
length 
Mono
-mer 
Units 
Chemical 
Info 
Structure 
5 
Chemical 
Formula: 
C49H36 
Na6 
O28S 
 
Molecular 
Weight: 
1242.80 
 
Elemental 
Analysis:  
C, 47.36 
H, 2.92 
Na, 11.10 
O, 36.05 
S, 2.58 
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7 
Chemical 
Formula: 
C69H52 
Na8 
O38S 
 
Molecular 
Weight: 
1705.12 
 
Elemental 
Analysis: 
 C, 48.60 
H, 3.07 
Na, 10.79 
O, 35.66 
S, 1.88 
 
8 
Chemical 
Formula: 
C79H58 
Na9 
O43S 
 
Molecular 
Weight: 
1934.26 
 
Elemental 
Analysis:  
C, 49.06 
H, 3.02 
Na, 10.70 
O, 35.57 
S, 1.66 
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10 
Chemical 
Formula: 
C99H71 
Na12O56S
2 
 
Molecular 
Weight: 
2496.60 
 
Elemental 
Analysis:  
C, 47.63 
H, 2.87 
Na, 11.05 
O, 35.89 
S, 2.57 
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13 
Chemical 
Formula: 
C129H93 
Na15O71S
2 
 
Molecular 
Weight: 
3188.06 
 
Elemental 
Analysis:  
C, 48.60 
H, 2.94 
Na, 10.82 
O, 35.63 
S, 2.01 
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5. Development Status of Sulfated LMWLs 
 Chapter 2 describes the in vitro biological activities and in vivo pharmacodynamics 
profile of the LMWL polymers, particularly for CDS which has shown promise in being 
developed as a much needed and not yet available an anti-emphysema agent. To this 
end, we sought to fill in the gap of information about the LMWLs, their structural 
composition and physicochemical characteristics, to further their development. Little is 
known about the exact structure of LMWLs, including linkage pattern, chain length, 
sulfation level, and degree of decarboxylation. With so many unknowns, defining the 
exact structure and physicochemical parameters is an impossible task. While previous 
study of the unsulfated LMWLs was used to approximate the molecular weight of the 
sulfated LMWLs, in this work we measured the sulfated LMWLs directly through SEC-
HPLC studies.   Although LMWLs cannot be described by one exact molecular weight, 
averages and percentages of chains falling in ranges of molecular weight give us an idea 
of the make-up of the polymer. The figures and tables below are a summary of our best 
estimates of the characteristics of the sulfated LMWLs to date.  
  The molecular weight distribution profile of CDS changes from bimodal when no 
surfactant is used in the mobile phase of the HPLC to unimodal when Tween 80 is used 
in the mobile phase (Figure 67). This indicates that some large molecular weight species, 
likely an aggregate of smaller molecular weight chains, are disrupted when surfactant is 
present. The unimodal profile of CDS acquired with surfactant is likely the most accurate 
representation of its molecular weight distribution. The MP of CDS of ~5700 Da is ~40% 
higher than the previously reported molecular weight of CDS: 3320 Da (Table 33). The 
molecular weight estimate of 5700 Da is more accurate than the previous estimate 
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because we measured CDS directly, whereas the previous estimate was calculated from 
extrapolations of SEC-HPLC data from CD. 
 
Figure 67. SEC-HPLC profile of CDS represents the average molecular weight 
distribution when no surfactant and 0.02% Tween 80 are used in the mobile phase 
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Table 33. Summary of physicochemical properties of CDS represents the average 
molecular weight distribution when no surfactant and 0.02% Tween 80 are used in the 
mobile phase 
Physicochemical Properties of CDS 
Mobile phase of HPLC 
No surfactant 0.02% Tween 80 
MP (Da) 
9121 ± 910 
(8211 – 9311) 
5742 ± 512 
(5230 – 6254) 
MN (Da) 
8604 ± 860 
(7744 – 9464) 
5513 ± 550 
(4963 – 6063) 
MW (Da) 
12242 ± 1200 
(11042 – 13442) 
14217 ± 1400 
(12817 – 15617) 
Polydispersity 1.42 ± 0.2 2.58 ± 0.4 
Chains < 6,000 Da 33% 65% 
Chains 6,000 – 10,000 Da 33% 17% 
Chains > 10,000 Da 33% 16% 
   
Total Sulfur Content 2.75% ± 1.14% 
Sulfation level per Monomeric Unit 0.4 
β-O-4 linkages ~70% 
β-5 linkages ~30% 
Log D 0.916 ± 0.089 
  
  The summary of physicochemical properties of CDS represents the extent of what 
is currently known about the character of this sulfated LMWL (Table 33).  
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 The SEC-HPLC profile of FDS followed a similar trend as that of CDS discussed 
above (Figure 68).  
 
Figure 68. SEC-HPLC profile of FDS represents the average molecular weight distribution 
when no surfactant and 0.02% Tween 80 are used in the mobile phase 
 The summary of physicochemical properties of FDS revealed that there is likely 
one sulfate group per every two monomer units (Table 34). FDS is more sulfated than 
CDS, which likely has one sulfate group every 2.5 monomer units. Like CDS, the log D of 
FDS was close to 1, indicating significant hydrophobic character of the charged polymers 
likely due to the contributions from their aromatic backbones. 
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Table 34. Summary of physicochemical properties of FDS 
Physicochemical Properties of FDS 
Mobile phase of HPLC 
No surfactant 0.02% Tween 80 
MP (Da) 
8338 ± 871 
(7467 – 9155) 
7470 ± 828 
(6642 – 8298) 
MN (Da) 
8251 ± 825 
(7426 – 9076) 
6586 ± 650 
(5936 – 7236) 
MW (Da) 
11622 ± 1100 
(10522 – 12722) 
17772 ± 1700 
(16072 – 19472) 
Polydispersity 1.41 ± 0.2 2.37 ± 0.4 
Chains < 6,000 Da 41% 51% 
Chains 6,000 – 10,000 Da 31% 11% 
Chains > 10,000 Da 28% 38% 
   
Sulfation level per Monomeric Unit 0.5 
Log D  0.97 ± 0.09 
 
 The SEC-HPLC profile of SDS followed a similar trend as the other sulfated 
LMWLs (Figure 69). 
 
Figure 69. SEC-HPLC profile of SDS represents the average molecular weight distribution 
when no surfactant and 0.02% Tween 80 are used in the mobile phase 
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 Less of the physicochemical properties of SDS could be determined than the other 
sulfated LMWLs due to anomalous results with its unsulfated precursor SD (Table 35).  
 
Table 35. Summary of physicochemical properties of SDS 
Physicochemical Properties of SDS 
Mobile phase of HPLC 
No surfactant 0.02% Tween 80 
MP (Da) 
7765 ± 228 
(7537 – 7993) 
4354 ± 162 
(4192 – 4516) 
MN (Da) 
6827 ± 680 
(6147 – 7507) 
3728 ± 370 
(3358 – 4098) 
MW (Da) 
8809 ± 880 
(7929 – 9689) 
12527 ± 1200 
(11327 – 13727) 
Polydispersity 1.29 ± 0.2  3.36 ± 0.4 
Chains < 6,000 Da 44% 85% 
Chains 6,000 – 10,000 Da 45% 10% 
Chains > 10,000 Da 11% 5% 
   
Log D 1.11 ± 0.11 
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6. The Effect of Lipids on Blood Coagulation 
6.1 Introduction  
Clinical evidence supports the idea that lipids and fatty acids effect blood 
coagulation (Table 37).89-6 Patients with spontaneous venous thromboembolism (VTE) 
have higher prevalence of atherosclerosis and higher triglyceride levels.89 High-density 
lipoprotein (HDL) is inversely and consistently correlated with VTE as well.90 Dyslipidemia 
is associated with hypercoagulability, endothelial dysfunction, and increased platelet 
aggregation.89 Atherosclerosis is associated with activation of both platelets and blood 
and an increase in fibrin turnover, which can lead to thrombotic complications.91 Statins, 
a drug class that decreases the liver’s production of cholesterol, are known to reduce the 
risk of VTE. 91 VTE is linked to low HDL levels and cholesteryl ester transfer protein 
(CETP) modulates HDL metabolism.90  
Clotting factors are known to associate with lipids at variable affinities and their 
binding modifies the activity of most clotting factors.92 Triglycerides and oxidized low-
density lipoprotein (LDL) accelerate activation of prothrombin, factor X, and factor VII.92 
Phosphatidylethanolamine, cardiolipin, neutral glycosphingolipds, and HDL enhance 
inactivation of factor Va by activated protein C.92 It has been shown that purified 
lipoproteins activate factor VII by factor Xa in vitro.92 Glucosylceramide is known to cause 
dose-dependent prolongation of prothrombin time in the presence of APC:protein S 
complex.93 Sphingosine and sphinganine down-regulate thrombin generation in the 
presence of factor Va, sphingosine and its analogs inhibit activation of prothrombin, and 
sphingosine dose dependently prolongs factor Xa dependent clotting times.94 Thrombin 
generation is also inhibited by glucosylsphingosine, lysosphingomyelin, 
phytosphingosine, and primary alkylamines with more than10 carbons.94 It has also been 
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established that a positively charged primary amino moiety and chain length of eight or 
more carbons are necessary for anticoagulant activity.94 Furthermore, free 
phosphatidylserine has been found to have an effect on prothrombin activation regardless 
of membrane association.95 Based on these literature findings, we seek to understand 
this association at a molecular level by studying the effect of lipids (and amino acids) on 
the clotting time of human plasma.  
Table 36. Structures of lipids chosen for clotting assay tests. 
Lipid/AA involved Effect on coagulation 
HDL cholesterol 
 
Triglycerides 
 
atherosclerosis 
HDL was lower in VTE patients 
 
VTE pts have higher trig/atherosclerosis89 
HDL HDL inversely and consistently correlated with VTE90 
Atherosclerosis Activates platelets 
Increases fibrin turnover91 
High D-Dimer levels Increased risk of VTE91 
Triglycerides 
Oxidized LDL 
Accelerate activation of of prothrombin, fX, and fVII92 
Phosphatidylethanolamine, 
cardiolipin, neutral 
glycosphingolipds, and 
HDL 
Enhance inactivation of fVa by activated protein C92 
Purified lipoproteins activate factor VII by factor Xa92 
Glucosylceramide Prolongs PT in the presence of APC:protein S 
complex93 
sphingosine, sphinganine, 
and stearylamine 
Inhibit prothrombin activation 
Anticoagulant property of Sphingosine and related 
compounds requires a hydrophobic side chain of more 
than 10 carbons as well as a positive charge94 
Sphingosine, sphinganine, 
glucosylsphingosine, 
lysosphingomyelin, 
phytosphingosine, primary 
alkylamines with more 
than10 carbons 
Inhibit thrombin generation 
Acylation of the amino group ablated anticoagulant 
activities94 
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6.2 Clotting Assays Methods 
Activated partial thromboplastin time (APTT) measures intrinsic coagulation factors 
(VIII, IX, XI, XII, and prekallikrein) and prothrombin time (PT) measures extrinsic factors 
(I (fibrinogen), II (prothrombin), V, VII, and X). Various lipids and amino acids were tested 
over a range of concentrations for effect on clotting time with a fibrometer and human 
plasma. The assay works by causing recalcification of plasma in the presence of tissue 
factor which activates factor Xa, which then activates prothrombin to thrombin, which 
converts fibrinogen to fibrin, forming an insoluble clot. The clot creates resistance that is 
detected by the needle of the fibrometer, the instrument stops, and time is recorded and 
compared to baseline (no lipid or amino acid added). 
 
 
 
 
 
Table 37. Literature findings of lipid and amino acid (AA) effects on blood coagulation 
Lipids 
Decanoic Acid 10:0 
 
Linoleic Acid 18:2 (cis, cis) 
 
Methyl Linoleate 18+1:2 (cis, cis) 
 
Stearic Acid 18:0 
 
Eladic Acid 18:1 (trans) 
 
Oleic Acid 18:1 
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Lipids tested included decanoic acid, linoleic acid, methyl linoleate, oleic acid, 
methyl oleate, stearic acid, elaidic acid, arachidonic acid, and ethyl arachidonate (Table 
36). Amino acids tested included serine, aspartic acid, lysine, alanine, glycine, and 
arginine.  Lipids that were not in liquid form at room temperature were dissolved in 
50mg/mL bovine serum albumin (BSA) in water, 50% glycerol in water, dimethyl sulfoxide 
(DMSO), and/or human blood plasma. Time taken by the plasma to clot was recorded at 
baseline and after the addition of lipids and amino acids, with the resultant concentrations 
of the lipid/amino acid in the assay from 0 to 20 mM. Activation time for the APTT test for 
the amino acids was 3 minutes and 5 minutes for the fatty acids.  
A variety of chain lengths from 10-20 carbons were chosen to be tested as part of 
the lipid library to look for an effect of increasing length on clotting (Table 36). Varying 
degrees and types of unsaturation (one vs two vs four double bonds; cis vs trans) were 
included among lipids of similar chain length for comparison. Finally, both carboxylic acid 
(negatively charged at physiological pH) and methylated/ethylated forms (no charge) 
were included to determine if anionic charge effects activity of the lipid on clotting 
differently than neutral charge. 
APTT and PT results are reported as “2x APTT” values and “2x PT” values that 
indicate the concentration of lipid/amino acid necessary to increase the clotting time two 
times over the baseline (when no lipid/amino acid was added) PT or APTT clotting time. 
A lower “2x” value means a lower concentration of the lipid or amino acid was needed to 
Methyl Oleate 18+1:1 (cis) 
 
Arachidonic Acid 20:4 (all cis) 
 
Ethyl Arachidonate 20+2:4 (all cis) 
 
142 
 
increase the baseline clotting time by 100%, therefore indicating a more potent 
anticoagulation activity. 
 6.3 Clotting Assay Results 
The majority of lipids and amino acids studied were found to have no significant 
effect on the basal clotting profile of normal human plasma in both APTT and PT tests, 
except for arachidonic acid, decanoic acid, linoleic acid, and oleic acid, which 
demonstrated a concentration dependent increase in APTT and PT.  Decanoic acid and 
arachidonic acid increased clotting time for both APTT and PT in a concentration 
dependent fashion more efficiently than the other lipids. Linoleic acid and oleic acid also 
showed an increase in clotting time at comparatively higher concentrations, however the 
ester forms (methyl linoleate, methyl oleate, and ethyl arachidonate) did not affect clotting 
time. The positively charged amino acids lysine and arginine increased clotting time for 
both APTT and PT in a concentration dependent fashion more efficiently than the other 
amino acids. When plasma was used as the solvent results of the assay were more 
reproducible than with the other solvents.  
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6.3.1 APTT Lipids 
 
 While many of the lipids tested did not significantly affect the APTT, arachidonic 
acid and decanoic acid increased the APTT in a dose dependent fashion (Figure 70). 
Decanoic acid had the most potent anticoagulant effect with a 2x APTT value of 9.7 mM, 
followed by arachidonic acid at 25.6 mM and oleic acid at 31 mM (Table 38).  
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Table 38. 2x APTT values for lipids representing the concentration of amino acid 
needed to increase the APTT 100% over baseline 
Lipid 2x APTT (mM) 
Arachidonic Acid 25.6 ± 2.5 
Decanoic Acid 9.7 ± 1 
Ethyl Arachidonate 49.2 ± 4.9 
Elaidic Acid 206 ± 20.6 
Linoleic Acid 43.4 ± 4.3 
Methyl Linoleate 466.5 ± 46.7 
Oleic Acid 31 ± 9.3 
Methyl Oleate 239.3 ± 23.9 
 
6.3.2 APTT Amino Acids 
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 Most amino acids did not significantly affect the APTT, but arginine and lysine 
increased the APTT in a dose dependent fashion (Figure 71). Arginine had the most 
potent anticoagulant effect with a 2x APTT value of 4.5 mM, followed by lysine with 11.9 
mM and aspartic acid with 14.7mM (Table 39). 
 
Table 39. 2x APTT values of amino acids representing the concentration of amino acid 
needed to increase the APTT 100% over baseline 
Amino Acid 2x APTT (mM) 
Alanine 234 ± 23 
Arginine 4.5 ± 0.5 
Aspartic Acid 14.7 ± 1.4 
Glycine 250 ± 25 
Lysine 11.9 ± 1.3 
Serine 71.1 ± 17.5 
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6.3.3 PT Lipids   
 
 Most of the lipids did not significantly affect the PT, but once again arachidonic and 
decanoic acid increased the PT in a dose dependent manner (Figure 72). Decanoic acid 
had the most potent anticoagulant effect with a 2x PT value of 41.1 mM, followed by 
arachidonic acid at 63 mM (Table 40).  
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Figure 72. PT results of lipids 
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Table 40. 2x PT values for lipids  representing the concentration of amino acid needed 
to increase the APTT 100% over baseline. (NA = not applicable; the lipid does not 
increase the APTT even at the highest concentrations tested) 
Lipid 2x PT (mM) 
Arachidonic Acid 63 ± 6.3 
Decanoic Acid 41.1 ± 4.1 
Ethyl Arachidonate 179.4 ± 18 
Elaidic Acid 277.8 ± 27.8 
Linoleic Acid 157 ± 15 
Methyl Linoleate NA 
Oleic Acid 266.3 ± 26.6 
Methyl Oleate NA 
 
6.3.4 PT Amino Acids   
 
 Most of the amino acids tested did not signifcantly affect the PT, but once again 
lysine and arginine increased the PT in a dose dependent manner (Figure 73). Arginine 
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had the most potent anticoagulant effect with a 2x PT of 9.1 mM, followed by lysine at 
18.6mM (Table 41). 
Table 41.2x PT values for amino acids  representing the concentration of amino acid 
needed to increase the APTT 100% over baseline. (NA = not applicable; the lipid does 
not increase the APTT even at the highest concentrations tested) 
Amino Acid 2x PT (mM) 
Alanine NA 
Arginine 9.1 ± 1 
Aspartic Acid 65.1 ± 6.5 
Glycine 227.3 ± 22.7 
Lysine 18.6 ± 1.9 
Serine 106.8 ± 10.7 
 
6.4 Conclusions 
It has been shown that increased triglyceride levels, atherosclerosis, and 
dyslipidemia are associated with thrombotic complications, but the causal mechanism of 
this connection is still being studied.1-6 We seek to develop a method using activated 
partial thromboplastin time (APTT) and prothrombin time (PT) tests to investigate the 
effect fatty acids have on clotting time of human plasma. Various lipids and amino acids 
were tested over a range of concentrations for effect on clotting time with a fibrometer to 
determine activated partial thromboplastin time (APTT) and prothrombin time (PT).   
The majority of lipids and amino acids studied were found to have no significant 
effect on the basal clotting profile of normal human plasma in both APTT and PT tests, 
except for arachidonic acid, decanoic acid, linoleic acid, oleic acid, lysine, and arginine 
which demonstrated a concentration dependent increase in APTT and PT.  Decanoic acid 
and arachidonic acid increased clotting time for both APTT and PT in a concentration 
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dependent fashion more efficiently than the other lipids. Linoleic acid and oleic acid also 
showed an increase in clotting time at comparatively higher concentrations than the other 
lipids, however the ester forms (methyl linoleate, methyl oleate, and ethyl arachidonate) 
did not affect clotting time.  
Comparison of results of the fatty acids versus the ester forms suggests the acid 
functional group may be responsible in some way for the molecules effect on clotting. 
Lysine and arginine, which are usually protonated at physiological pH, having a more 
pronounced effect on increasing clotting times compared to the other amino acids points 
towards the positive amino moiety as potentially being responsible for the effect. There is 
a clear in vitro effect of lipids on clotting time and more work is needed to determine which 
lipids effect the clotting cascade and in what way.  Also, these results with simple fatty 
acids and amino acids suggest that complex lipids should be screened for their anti- and 
pro-coagulant properties.  
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Appendix 1 
CDS 
Table 42. SEC-HPLC chromatograms of batch CDSMT1 acquired with no surfactant and 
three increasing concentrations of Tween 80 in the mobile phase. (Three individual trials 
for each mobile phase, grouped by mobile phase; Absorbance units: mAU) 
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Table 43. SEC-HPLC chromatograms of batch CDSMT2 acquired with no surfactant and 
three increasing concentrations of Tween 80 in the mobile phase. (Three individual trials 
for each mobile phase, grouped by mobile phase; Absorbance units: mAU) 
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Without Surfactant 0.01% Tween 80 
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Table 44. SEC-HPLC chromatograms of batch CDSBH acquired with no surfactant and 
three increasing concentrations of Tween 80 in the mobile phase. (Three individual trials 
for each mobile phase, grouped by mobile phase; Absorbance units: mAU) 
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Without Surfactant 0.01% Tween 80 
  
0.02% Tween 80 0.05% Tween 80 
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FDS 
Table 45. SEC-HPLC chromatograms of batch FDSMT acquired with no surfactant and 
three increasing concentrations of Tween 80 in the mobile phase. (Three individual trials 
for each mobile phase, grouped by mobile phase; Absorbance units: mAU) 
FDSMT 
Without Surfactant 0.01% Tween 80 
  
0.02% Tween 80 0.05% Tween 80 
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Table 46. SEC-HPLC chromatograms of batch FDSJT acquired with no surfactant and 
three increasing concentrations of Tween 80 in the mobile phase. (Three individual trials 
for each mobile phase and one additional trial with 0.02% Tween 80, grouped by mobile 
phase; Absorbance units: mAU) 
FDSJT 
Without Surfactant 0.01% Tween 80 
  
0.02% Tween 80 0.05% Tween 80 
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Table 47.SEC-HPLC chromatograms of batch FDSBH acquired with no surfactant and 
three increasing concentrations of Tween 80 in the mobile phase. (Three individual trials 
for each mobile phase, grouped by mobile phase; Absorbance units: mAU) 
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-1000
1000
3000
5000
7000
9000
11000
13000
15000
4 6 8 10
A
b
s
Elution Volume (mL)
FDS BH 1
FDS BH 2
FDS BH 3
-5000
0
5000
10000
15000
20000
11 13 15
A
b
s
Elution Volume (mL)
FDS BH 1
FDS BH 2
FDS BH 3
-2000
0
2000
4000
6000
8000
10000
12000
14000
16000
5 7 9 11
A
b
so
rb
an
ce
  (
m
A
U
)
Elution Volume (mL)
FDS BH 1
FDS BH 2
FDS BH 3
-2000
0
2000
4000
6000
8000
10000
12000
11 13 15
A
b
s
Elution Volume (mL)
FDS BH 1
FDS BH 2
FDS BH 3
161 
 
 
Appendix 2 
SDS Unsulfated DHPs 
 
 Standards 
  
  
Figure 74. SEC-HPLC Chromatograms of SDS, unsulfated DHPs, and controls with 
0.02% Triton X-100 in the mobile phase  
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